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Preamble
It is important that the medical profession play a significant role in
critically evaluating the use of diagnostic procedures and therapies
as they are introduced and tested in the detection, management, or
prevention of disease states. Rigorous and expert analysis of the
available data documenting absolute and relative benefits and risks
of those procedures and therapies can produce helpful guidelines
that improve the effectiveness of care, optimize patient outcomes,
and favorably affect the overall cost of care by focusing resources
on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly en-
gaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task Force
on Practice Guidelines, whose charge is to develop, update, or
revise practice guidelines for important cardiovascular diseases
and procedures, directs this effort. The Task Force is pleased to
have this guideline developed in conjunction with the European
Society of Cardiology (ESC). Writing committees are charged
with the task of performing an assessment of the evidence and
acting as an independent group of authors to develop or update
written recommendations for clinical practice.
Experts in the subject under consideration have been selected
from all 3 organizations to examine subject-specific data and to
write guidelines. The process includes additional representatives
from other medical practitioner and specialty groups when appro-
priate. Writing committees are specifically charged to perform a
formal literature review, weigh the strength of evidence for or
against a particular treatment or procedure, and include estimates of
expected health outcomes where data exist. Patient-specific modi-
fiers, comorbidities, and issues of patient preference that might
influence the choice of particular tests or therapies are considered as
well as frequency of follow-up and cost-effectiveness. When avail-
able, information from studies on cost will be considered; however,
review of data on efficacy and clinical outcomes will constitute the
primary basis for preparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and the
ESC Committee for Practice Guidelines make every effort to
avoid any actual, potential, or perceived conflict of interest that
might arise as a result of an outside relationship or personal
interest of the Writing Committee. Specifically, all members of
the Writing Committee and peer reviewers of the document are
asked to provide disclosure statements of all such relationships
that might be perceived as real or potential conflicts of interest.
Writing Committee members are also strongly encouraged to
declare a previous relationship with industry that might be
perceived as relevant to guideline development. If a Writing
Committee member develops a new relationship with industry
during his or her tenure, he or she is required to notify guideline
staff in writing. The continued participation of the Writing
Committee member will be reviewed. These statements are
reviewed by the parent Task Force, reported orally to all
members of the Writing Committee at each meeting, and
updated and reviewed by the Writing Committee as changes
occur. Please refer to the methodology manuals for further
description of the policies used in guideline development,
including relationships with industry, available on the ACC,
AHA, and ESC World Wide Web sites (http://www.acc.org/
clinical/manual/manual_introltr.htm, http://circ.ahajournals.org/
manual/ and http://www.escardio.org/knowledge/guidelines/
Rules/). Please see Appendix I for author relationships with
industry and Appendix II for peer reviewer relationships with
industry that are pertinent to these guidelines.
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range of
generally acceptable approaches for the diagnosis, manage-
ment, and prevention of specific diseases and conditions.
These guidelines attempt to define practices that meet the
needs of most patients in most circumstances. These guide-
line recommendations reflect a consensus of expert opinion
after a thorough review of the available, current scientific
evidence and are intended to improve patient care. If these
guidelines are used as the basis for regulatory/payer deci-
sions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and the patient in light of all of the circumstances
presented by that patient. There are circumstances in which
deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
Task Force on Practice Guidelines and the ESC Committee for
Practice Guidelines and will be considered current unless they are
updated, revised, or sunsetted and withdrawn from distribution. The
executive summary and recommendations are published in the
August 15, 2006, issue of the Journal of the American College of
Cardiology, August 15, 2006, issue of Circulation, and August 16,
2006, issue of the European Heart Journal. The full-text guidelines
are e-published in the same issues of the journals noted above, as
well as posted on the ACC (www.acc.org), AHA (www.american-
heart.org), and ESC (www.escardio.org) World Wide Web sites.
Copies of the full text and the executive summary are available from
all 3 organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA, FESC, Chair,
ACC/AHA Task Force on Practice Guidelines
Silvia G. Priori, MD, PhD, FESC, Chair, ESC Committee
for Practice Guidelines
I. Introduction
A. Organization of Committee and Evidence
Review
Atrial fibrillation (AF) is the most common sustained cardiac
rhythm disturbance, increasing in prevalence with age. AF is
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TABLE 1. Applying Classification of Recommendations and Level of Evidence†
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Class I Class IIa Class IIb Class III
Benefit  Risk Benefit  Risk Benefit  Risk Risk  Benefit
Additional studies with focused objectives
needed
Additional studies with broad objectives needed;
additional registry data would be helpful
No additional studies needed
Procedure/treatment SHOULD be
performed/administered
IT IS REASONABLE to perform
procedure/administer treatment
Procedure/treatment MAY BE CONSIDERED Procedure/treatment should NOT be
performed/administered SINCE IT IS NOT HELPFUL
AND MAY BE HARMFUL
Level A
Multiple (3 to 5) population
risk strata evaluated*
General consistency of
direction and magnitude of
effect
• Recommendation that procedure or
treatment is useful/effective
• Sufficient evidence from multiple
randomized trials or meta-analyses
• Recommendation in favor of treatment or
procedure being useful/effective
• Some conflicting evidence from multiple
randomized trials or meta-analyses
• Recommendation’s usefulness/efficacy less well
established
•Greater conflicting evidence from multiple
randomized trials or meta-analyses
• Recommendation that procedure or treatment is
not useful/effective and may be harmful
• Sufficient evidence from multiple randomized trials
or meta-analyses
Level B
Limited (2 to 3) population risk
strata evaluated*
• Recommendation that procedure or
treatment is useful/effective
• Limited evidence from single randomized
trial or nonrandomized studies
• Recommendation in favor of treatment or
procedure being useful/effective
• Some conflicting evidence from single
randomized trial or nonrandomized studies
• Recommendation’s usefulness/efficacy less well
established
•Greater conflicting evidence from single
randomized trial or nonrandomized studies
• Recommendation that procedure or treatment is
not useful/effective and may be harmful
• Limited evidence from single randomized trial or
nonrandomized studies
Level C
Very limited (1 to 2) population
risk strata evaluated*
• Recommendation that procedure or
treatment is useful/effective
•Only expert opinion, case studies, or
standard-of-care
• Recommendation in favor of treatment or
procedure being useful/effective
•Only diverging expert opinion, case studies, or
standard-of-care
• Recommendation’s usefulness/efficacy less well
established
•Only diverging expert opinion, case studies, or
standard-of-care
• Recommendation that procedure or treatment is
not useful/effective and may be harmful
•Only expert opinion, case studies, or
standard-of-care
*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. A
recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not
available, there may be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACC/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline recommendations have been written in full sentences that express a complete
thought, such that a recommendation, even if separated and presented apart from the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this
will increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
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often associated with structural heart disease, although a
substantial proportion of patients with AF have no detect-
able heart disease. Hemodynamic impairment and throm-
boembolic events related to AF result in significant mor-
bidity, mortality, and cost. Accordingly, the American
College of Cardiology (ACC), the American Heart Asso-
ciation (AHA), and the European Society of Cardiology
(ESC) created a committee to establish guidelines for
optimum management of this frequent and complex
arrhythmia.
The committee was composed of representatives of the
ACC, AHA, ESC, the European Heart Rhythm Association
(EHRA), and the Heart Rhythm Society (HRS). The docu-
ment was reviewed by reviewers nominated by these organi-
zations and will be reviewed annually by the Task Force and
considered current unless the Task Force revises or with-
draws it from distribution.
The ACC/AHA/ESC Writing Committee to Revise the
2001 Guidelines for the Management of Patients With Atrial
Fibrillation conducted a comprehensive review of the rele-
vant literature from 2001 to 2006 using the PubMed/MED-
LINE and Cochrane Library databases. Searches focused on
English-language sources and studies in human subjects.
Articles related to animal experimentation were cited when
important to understanding concepts pertinent to patient
management.
Classification of Recommendations
• Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/therapy is bene-
ficial, useful, and effective.
• Class II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of performing the procedure/therapy.
 Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
 Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
• Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not useful or
effective and in some cases may be harmful.
Level of Evidence
The weight of evidence was ranked from highest (A) to
lowest (C), as follows:
• Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
• Level of Evidence B: Data derived from a single random-
ized trial, or nonrandomized studies.
• Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
B. Changes Since the Initial Publication of These
Guidelines in 2001
The Writing Committee considered evidence published since
2001 and drafted revised recommendations to incorporate
results from major clinical trials such as those that compared
rhythm control and rate control approaches to long-term
management. The text has been reorganized to reflect the
implications for patient care, beginning with recognition of
AF and its pathogenesis and the general priorities of rate
control, prevention of thromboembolism, and methods avail-
able for use in selected patients to correct the arrhythmia and
maintain normal sinus rhythm. Advances in catheter-based
ablation technologies are incorporated in expanded sections
and recommendations, with the recognition that such vital
details as patient selection, optimum catheter positioning,
absolute rates of treatment success, and the frequency of
complications remain incompletely defined. Sections on drug
therapy have been confined to human studies with com-
pounds approved for clinical use in North America and/or
Europe. As data on the management of patients prone to AF
in special circumstances are more robust, recommendations
are based on a higher level of evidence than in the first edition
of these guidelines. Every effort was made to maintain
consistency with other ACC/AHA and ESC practice
guidelines.
C. Recommendations for Management of Patients
With Atrial Fibrillation
Classification of Recommendations and Level of Evidence
are expressed in the ACC/AHA/ESC format as follows and
described in Table 1. Recommendations are evidence
based and derived primarily from published data. The
reader is referred to the full-text guidelines for a complete
description of the rationale and evidence supporting these
recommendations.
Recommendations
1. Pharmacological Rate Control During Atrial
Fibrillation
Class I
1. Measurement of the heart rate at rest and control
of the rate using pharmacological agents (either a
beta blocker or nondihydropyridine calcium
channel antagonist, in most cases) are recom-
mended for patients with persistent or permanent
AF. (Level of Evidence: B)
2. In the absence of preexcitation, intravenous ad-
ministration of beta blockers (esmolol, metopro-
lol, or propranolol) or nondihydropyridine cal-
cium channel antagonists (verapamil, diltiazem) is
recommended to slow the ventricular response to
AF in the acute setting, exercising caution in
patients with hypotension or heart failure (HF).
(Level of Evidence: B)
3. Intravenous administration of digoxin or amiod-
arone is recommended to control the heart rate in
patients with AF and HF who do not have an
accessory pathway. (Level of Evidence: B)
4. In patients who experience symptoms related to AF
during activity, the adequacy of heart rate control
should be assessed during exercise, adjusting phar-
macological treatment as necessary to keep the rate
in the physiological range. (Level of Evidence: C)
5. Digoxin is effective following oral administration
to control the heart rate at rest in patients with AF
and is indicated for patients with HF, left ventric-
ular (LV) dysfunction, or for sedentary individu-
als. (Level of Evidence: C)
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Class IIa
1. A combination of digoxin and either a beta
blocker or nondihydropyridine calcium channel
antagonist is reasonable to control the heart rate
both at rest and during exercise in patients with
AF. The choice of medication should be individu-
alized and the dose modulated to avoid bradycar-
dia. (Level of Evidence: B)
2. It is reasonable to use ablation of the AV node or
accessory pathway to control heart rate when phar-
macological therapy is insufficient or associated with
side effects. (Level of Evidence: B)
3. Intravenous amiodarone can be useful to con-
trol the heart rate in patients with AF when
other measures are unsuccessful or contraindi-
cated. (Level of Evidence: C)
4. When electrical cardioversion is not necessary
in patients with AF and an accessory pathway,
intravenous procainamide or ibutilide is a rea-
sonable alternative. (Level of Evidence: C)
Class IIb
1. When the ventricular rate cannot be adequately
controlled both at rest and during exercise in
patients with AF using a beta blocker, nondihy-
dropyridine calcium channel antagonist, or
digoxin, alone or in combination, oral amiodarone
may be administered to control the heart rate.
(Level of Evidence: C)
2. Intravenous procainamide, disopyramide, ibuti-
lide, or amiodarone may be considered for
hemodynamically stable patients with AF in-
volving conduction over an accessory pathway.
(Level of Evidence: B)
3. When the rate cannot be controlled with pharma-
cological agents or tachycardia-mediated cardio-
myopathy is suspected, catheter-directed ablation
of the AV node may be considered in patients with
AF to control the heart rate. (Level of Evidence: C)
Class III
1. Digitalis should not be used as the sole agent to
control the rate of ventricular response in patients
with paroxysmal AF. (Level of Evidence: B)
2. Catheter ablation of the AV node should not be
attempted without a prior trial of medication to
control the ventricular rate in patients with AF.
(Level of Evidence: C)
3. In patients with decompensated HF and AF,
intravenous administration of a nondihydro-
pyridine calcium channel antagonist may exac-
erbate hemodynamic compromise and is not
recommended. (Level of Evidence: C)
4. Intravenous administration of digitalis glyco-
sides or nondihydropyridine calcium channel
antagonists to patients with AF and a preexci-
tation syndrome may paradoxically accelerate
the ventricular response and is not recom-
mended. (Level of Evidence: C)
2. Preventing Thromboembolism
(For recommendations regarding antithrombotic
therapy in patients with AF undergoing cardiover-
sion, see Section I.C.3.d.)
Class I
1. Antithrombotic therapy to prevent thromboem-
bolism is recommended for all patients with AF,
except those with lone AF or contraindications.
(Level of Evidence: A)
2. The selection of the antithrombotic agent should be
based upon the absolute risks of stroke and bleeding
and the relative risk and benefit for a given patient.
(Level of Evidence: A)
3. For patients without mechanical heart valves at
high risk of stroke, chronic oral anticoagulant
therapy with a vitamin K antagonist is recom-
mended in a dose adjusted to achieve the target
intensity international normalized ratio (INR)
of 2.0 to 3.0, unless contraindicated. Factors
associated with highest risk for stroke in pa-
tients with AF are prior thromboembolism
(stroke, transient ischemic attack [TIA], or sys-
temic embolism) and rheumatic mitral stenosis.
(Level of Evidence: A)
4. Anticoagulation with a vitamin K antagonist is
recommended for patients with more than 1 mod-
erate risk factor. Such factors include age 75 y or
greater, hypertension, HF, impaired LV systolic
function (ejection fraction 35% or less or frac-
tional shortening less than 25%), and diabetes
mellitus. (Level of Evidence: A)
5. INR should be determined at least weekly during
initiation of therapy and monthly when anticoagu-
lation is stable. (Level of Evidence: A)
6. Aspirin, 81–325 mg daily, is recommended as an
alternative to vitamin K antagonists in low-risk
patients or in those with contraindications to oral
anticoagulation. (Level of Evidence: A)
7. For patients with AF who have mechanical
heart valves, the target intensity of anticoagu-
lation should be based on the type of prosthesis,
maintaining an INR of at least 2.5. (Level of
Evidence: B)
8. Antithrombotic therapy is recommended for
patients with atrial flutter as for those with AF.
(Level of Evidence: C)
Class IIa
1. For primary prevention of thromboembolism
in patients with nonvalvular AF who have
just 1 of the following validated risk factors,
antithrombotic therapy with either aspirin or
a vitamin K antagonist is reasonable, based
upon an assessment of the risk of bleeding
complications, ability to safely sustain ad-
justed chronic anticoagulation, and patient
preferences: age greater than or equal to 75 y
(especially in female patients), hypertension,
HF, impaired LV function, or diabetes melli-
tus. (Level of Evidence: A)
2. For patients with nonvalvular AF who have 1 or
more of the following less well-validated risk fac-
tors, antithrombotic therapy with either aspirin or
a vitamin K antagonist is reasonable for preven-
tion of thromboembolism: age 65 to 74 y, fe-
male gender, or CAD. The choice of agent should
be based upon the risk of bleeding complications,
ability to safely sustain adjusted chronic anticoag-
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ulation, and patient preferences. (Level of Evi-
dence: B)
3. It is reasonable to select antithrombotic therapy
using the same criteria irrespective of the pat-
tern (i.e., paroxysmal, persistent, or permanent)
of AF. (Level of Evidence: B)
4. In patients with AF who do not have mechanical
prosthetic heart valves, it is reasonable to inter-
rupt anticoagulation for up to 1 wk without
substituting heparin for surgical or diagnostic
procedures that carry a risk of bleeding. (Level
of Evidence: C)
5. It is reasonable to reevaluate the need for
anticoagulation at regular intervals. (Level of
Evidence: C)
Class IIb
1. In patients 75 y of age and older at increased risk
of bleeding but without frank contraindications to
oral anticoagulant therapy, and in other patients
with moderate risk factors for thromboembolism
who are unable to safely tolerate anticoagulation
at the standard intensity of INR 2.0 to 3.0, a lower
INR target of 2.0 (range 1.6 to 2.5) may be
considered for primary prevention of ischemic
stroke and systemic embolism. (Level of Evidence:
C)
2. When surgical procedures require interruption
of oral anticoagulant therapy for longer than 1
wk in high-risk patients, unfractionated hepa-
rin may be administered or low-molecular-
weight heparin given by subcutaneous injection,
although the efficacy of these alternatives in this
situation is uncertain. (Level of Evidence: C)
3. Following percutaneous coronary intervention or
revascularization surgery in patients with AF,
low-dose aspirin (less than 100 mg per d) and/or
clopidogrel (75 mg per d) may be given concur-
rently with anticoagulation to prevent myocardial
ischemic events, but these strategies have not been
thoroughly evaluated and are associated with an
increased risk of bleeding. (Level of Evidence: C)
4. In patients undergoing percutaneous coronary
intervention, anticoagulation may be inter-
rupted to prevent bleeding at the site of periph-
eral arterial puncture, but the vitamin K antag-
onist should be resumed as soon as possible
after the procedure and the dose adjusted to
achieve an INR in the therapeutic range. Aspi-
rin may be given temporarily during the hiatus,
but the maintenance regimen should then con-
sist of the combination of clopidogrel, 75 mg
daily, plus warfarin (INR 2.0 to 3.0). Clopi-
dogrel should be given for a minimum of 1 mo
after implantation of a bare metal stent, at least
3 mo for a sirolimus-eluting stent, at least 6 mo
for a paclitaxel-eluting stent, and 12 mo or
longer in selected patients, following which war-
farin may be continued as monotherapy in the
absence of a subsequent coronary event. When
warfarin is given in combination with clopi-
dogrel or low-dose aspirin, the dose intensity
must be carefully regulated. (Level of Evidence:
C)
5. In patients with AF younger than 60 y without
heart disease or risk factors for thromboembolism
(lone AF), the risk of thromboembolism is low
without treatment and the effectiveness of aspirin
for primary prevention of stroke relative to the
risk of bleeding has not been established. (Level of
Evidence: C)
6. In patients with AF who sustain ischemic stroke
or systemic embolism during treatment with low-
intensity anticoagulation (INR 2.0 to 3.0), rather
than add an antiplatelet agent, it may be reason-
able to raise the intensity of the anticoagulation to
a maximum target INR of 3.0 to 3.5. (Level of
Evidence: C)
Class III
Long-term anticoagulation with a vitamin K an-
tagonist is not recommended for primary preven-
tion of stroke in patients below the age of 60 y
without heart disease (lone AF) or any risk factors
for thromboembolism. (Level of Evidence: C)
3. Cardioversion of Atrial Fibrillation
a. Pharmacological Cardioversion
Class I
Administration of flecainide, dofetilide,
propafenone, or ibutilide is recommended for
pharmacological cardioversion of AF. (Level of
Evidence: A)
Class IIa
1. Administration of amiodarone is a reasonable
option for pharmacological cardioversion of
AF. (Level of Evidence: A)
2. A single oral bolus dose of propafenone or
flecainide (“pill-in-the-pocket”) can be ad-
ministered to terminate persistent AF outside
the hospital once treatment has proved safe in
hospital for selected patients without sinus or
AV node dysfunction, bundle-branch block,
QT-interval prolongation, the Brugada syn-
drome, or structural heart disease. Before
antiarrhythmic medication is initiated, a beta
blocker or nondihydropyridine calcium chan-
nel antagonist should be given to prevent
rapid AV conduction in the event atrial flut-
ter occurs. (Level of Evidence: C)
3. Administration of amiodarone can be benefi-
cial on an outpatient basis in patients with
paroxysmal or persistent AF when rapid res-
toration of sinus rhythm is not deemed nec-
essary. (Level of Evidence: C)
Class IIb
Administration of quinidine or procainamide might
be considered for pharmacological cardioversion of
AF, but the usefulness of these agents is not well
established. (Level of Evidence: C)
Class III
1. Digoxin and sotalol may be harmful when
used for pharmacological cardioversion of
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AF and are not recommended. (Level of Evi-
dence: A)
2. Quinidine, procainamide, disopyramide, and
dofetilide should not be started out of hospital
for conversion of AF to sinus rhythm. (Level
of Evidence: B)
b. Direct-Current Cardioversion
Class I
1. When a rapid ventricular response does not
respond promptly to pharmacological mea-
sures for patients with AF with ongoing myo-
cardial ischemia, symptomatic hypotension,
angina, or HF, immediate R-wave synchro-
nized direct-current cardioversion is recom-
mended. (Level of Evidence: C)
2. Immediate direct-current cardioversion is
recommended for patients with AF involving
preexcitation when very rapid tachycardia or
hemodynamic instability occurs. (Level of Ev-
idence: B)
3. Cardioversion is recommended in patients
without hemodynamic instability when symp-
toms of AF are unacceptable to the patient. In
case of early relapse of AF after cardiover-
sion, repeated direct-current cardioversion
attempts may be made following administra-
tion of antiarrhythmic medication. (Level of
Evidence: C)
Class IIa
1. Direct-current cardioversion can be useful to
restore sinus rhythm as part of a long-term
management strategy for patients with AF.
(Level of Evidence: B)
2. Patient preference is a reasonable consideration
in the selection of infrequently repeated cardio-
versions for the management of symptomatic or
recurrent AF. (Level of Evidence: C)
Class III
1. Frequent repetition of direct-current cardio-
version is not recommended for patients who
have relatively short periods of sinus rhythm
between relapses of AF after multiple cardio-
version procedures despite prophylactic antiar-
rhythmic drug therapy. (Level of Evidence: C)
2. Electrical cardioversion is contraindicated in
patients with digitalis toxicity or hypokale-
mia. (Level of Evidence: C)
c. Pharmacological Enhancement of Direct-Current
Cardioversion
Class IIa
1. Pretreatment with amiodarone, flecainide,
ibutilide, propafenone, or sotalol can be use-
ful to enhance the success of direct-current
cardioversion and prevent recurrent AF.
(Level of Evidence: B)
2. In patients who relapse to AF after successful
cardioversion, it can be useful to repeat the
procedure following prophylactic administra-
tion of antiarrhythmic medication. (Level of
Evidence: C)
Class IIb
1. For patients with persistent AF, administration
of beta blockers, disopyramide, diltiazem,
dofetilide, procainamide, or verapamil may be
considered, although the efficacy of these agents
to enhance the success of direct-current cardio-
version or to prevent early recurrence of AF is
uncertain. (Level of Evidence: C)
2. Out-of-hospital initiation of antiarrhythmic
medications may be considered in patients
without heart disease to enhance the success
of cardioversion of AF. (Level of Evidence: C)
3. Out-of-hospital administration of antiar-
rhythmic medications may be considered to
enhance the success of cardioversion of AF in
patients with certain forms of heart disease
once the safety of the drug has been verified
for the patient. (Level of Evidence: C)
d. Prevention of Thromboembolism in Patients With
Atrial Fibrillation Undergoing Cardioversion
Class I
1. For patients with AF of 48-h duration or
longer, or when the duration of AF is unknown,
anticoagulation (INR 2.0 to 3.0) is recom-
mended for at least 3 wk prior to and 4 wk after
cardioversion, regardless of the method (elec-
trical or pharmacological) used to restore sinus
rhythm. (Level of Evidence: B)
2. For patients with AF of more than 48-h
duration requiring immediate cardioversion
because of hemodynamic instability, heparin
should be administered concurrently (unless
contraindicated) by an initial intravenous bo-
lus injection followed by a continuous infu-
sion in a dose adjusted to prolong the acti-
vated partial thromboplastin time to 1.5 to 2
times the reference control value. Thereafter,
oral anticoagulation (INR 2.0 to 3.0) should
be provided for at least 4 wk, as for patients
undergoing elective cardioversion. Limited
data support subcutaneous administration of
low-molecular-weight heparin in this indica-
tion. (Level of Evidence: C)
3. For patients with AF of less than 48-h duration
associated with hemodynamic instability (an-
gina pectoris, myocardial infarction [MI],
shock, or pulmonary edema), cardioversion
should be performed immediately without de-
lay for prior initiation of anticoagulation. (Level
of Evidence: C)
Class IIa
1. During the 48 h after onset of AF, the need
for anticoagulation before and after cardio-
version may be based on the patient’s risk of
thromboembolism. (Level of Evidence: C)
2. As an alternative to anticoagulation prior to car-
dioversion of AF, it is reasonable to perform
transesophageal echocardiography (TEE) in
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search of thrombus in the left atrium (LA) or left
atrial appendage (LAA). (Level of Evidence: B)
2a. For patients with no identifiable throm-
bus, cardioversion is reasonable imme-
diately after anticoagulation with un-
fractionated heparin (e.g., initiated by
intravenous bolus injection and an infu-
sion continued at a dose adjusted to
prolong the activated partial thrombo-
plastin time to 1.5 to 2 times the control
value until oral anticoagulation has
been established with an oral vitamin K
antagonist (e.g., warfarin) as evidenced
by an INR equal to or greater than 2.0).
(Level of Evidence: B) Thereafter, con-
tinuation of oral anticoagulation (INR
2.0 to 3.0) is reasonable for a total
anticoagulation period of at least 4 wk,
as for patients undergoing elective car-
dioversion. (Level of Evidence: B) Lim-
ited data are available to support the
subcutaneous administration of a low-
molecular-weight heparin in this indica-
tion. (Level of Evidence: C)
2b. For patients in whom thrombus is identi-
fied by TEE, oral anticoagulation (INR
2.0 to 3.0) is reasonable for at least 3 wk
prior to and 4 wk after restoration of
sinus rhythm, and a longer period of
anticoagulation may be appropriate even
after apparently successful cardioversion,
because the risk of thromboembolism of-
ten remains elevated in such cases. (Level
of Evidence: C)
3. For patients with atrial flutter undergoing
cardioversion, anticoagulation can be benefi-
cial according to the recommendations as for
patients with AF. (Level of Evidence: C)
4. Maintenance of Sinus Rhythm
Class I
Before initiating antiarrhythmic drug therapy,
treatment of precipitating or reversible causes of
AF is recommended. (Level of Evidence: C)
Class IIa
1. Pharmacological therapy can be useful in pa-
tients with AF to maintain sinus rhythm and
prevent tachycardia-induced cardiomyopathy.
(Level of Evidence: C)
2. Infrequent, well-tolerated recurrence of AF is
reasonable as a successful outcome of antiar-
rhythmic drug therapy. (Level of Evidence: C)
3. Outpatient initiation of antiarrhythmic drug
therapy is reasonable in patients with AF who
have no associated heart disease when the agent
is well tolerated. (Level of Evidence: C)
4. In patients with lone AF without structural
heart disease, initiation of propafenone or fle-
cainide can be beneficial on an outpatient basis
in patients with paroxysmal AF who are in sinus
rhythm at the time of drug initiation. (Level of
Evidence: B)
5. Sotalol can be beneficial in outpatients in sinus
rhythm with little or no heart disease, prone to
paroxysmal AF, if the baseline uncorrected QT
interval is less than 460 ms, serum electrolytes
are normal, and risk factors associated with
class III drug–related proarrhythmia are not
present. (Level of Evidence: C)
6. Catheter ablation is a reasonable alternative to
pharmacological therapy to prevent recurrent
AF in symptomatic patients with little or no LA
enlargement. (Level of Evidence: C)
Class III
1. Antiarrhythmic therapy with a particular drug
is not recommended for maintenance of sinus
rhythm in patients with AF who have well-
defined risk factors for proarrhythmia with
that agent. (Level of Evidence: A)
2. Pharmacological therapy is not recommended for
maintenance of sinus rhythm in patients with
advanced sinus node disease or atrioventricular
(AV) node dysfunction unless they have a func-
tioning electronic cardiac pacemaker. (Level of
Evidence: C)
5. Special Considerations
a. Postoperative Atrial Fibrillation
Class I
1. Unless contraindicated, treatment with an
oral beta blocker to prevent postoperative AF
is recommended for patients undergoing car-
diac surgery. (Level of Evidence: A)
2. Administration of AV nodal blocking agents
is recommended to achieve rate control in
patients who develop postoperative AF.
(Level of Evidence: B)
Class IIa
1. Preoperative administration of amiodarone re-
duces the incidence of AF in patients undergo-
ing cardiac surgery and represents appropriate
prophylactic therapy for patients at high risk
for postoperative AF. (Level of Evidence: A)
2. It is reasonable to restore sinus rhythm by
pharmacological cardioversion with ibutilide
or direct-current cardioversion in patients
who develop postoperative AF as advised for
nonsurgical patients. (Level of Evidence: B)
3. It is reasonable to administer antiarrhythmic
medications in an attempt to maintain sinus
rhythm in patients with recurrent or refractory
postoperative AF, as recommended for other
patients who develop AF. (Level of Evidence: B)
4. It is reasonable to administer antithrombotic
medication in patients who develop postoper-
ative AF, as recommended for nonsurgical
patients. (Level of Evidence: B)
Class IIb
Prophylactic administration of sotalol may be
considered for patients at risk of developing AF
following cardiac surgery. (Level of Evidence: B)
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b. Acute Myocardial Infarction
Class I
1. Direct-current cardioversion is recom-
mended for patients with severe hemodynam-
ic compromise or intractable ischemia, or
when adequate rate control cannot be
achieved with pharmacological agents in pa-
tients with acute MI and AF. (Level of Evi-
dence: C)
2. Intravenous administration of amiodarone is
recommended to slow a rapid ventricular
response to AF and improve LV function in
patients with acute MI. (Level of Evidence: C)
3. Intravenous beta blockers and nondihydro-
pyridine calcium antagonists are recom-
mended to slow a rapid ventricular response
to AF in patients with acute MI who do not
display clinical LV dysfunction, bronchos-
pasm, or AV block. (Level of Evidence: C)
4. For patients with AF and acute MI, adminis-
tration of unfractionated heparin by either con-
tinuous intravenous infusion or intermittent
subcutaneous injection is recommended in a
dose sufficient to prolong the activated partial
thromboplastin time to 1.5 to 2 times the con-
trol value, unless contraindications to anticoag-
ulation exist. (Level of Evidence: C)
Class IIa
Intravenous administration of digitalis is rea-
sonable to slow a rapid ventricular response and
improve LV function in patients with acute MI
and AF associated with severe LV dysfunction
and HF. (Level of Evidence: C)
Class III
The administration of class IC antiarrhythmic
drugs is not recommended in patients with AF in
the setting of acute MI. (Level of Evidence: C)
c. Management of Atrial Fibrillation Associated With
the Wolff-Parkinson-White (WPW) Preexcitation
Syndrome
Class I
1. Catheter ablation of the accessory pathway is
recommended in symptomatic patients with
AF who have WPW syndrome, particularly
those with syncope due to rapid heart rate or
those with a short bypass tract refractory
period. (Level of Evidence: B)
2. Immediate direct-current cardioversion is
recommended to prevent ventricular fibrilla-
tion in patients with a short anterograde
bypass tract refractory period in whom AF
occurs with a rapid ventricular response as-
sociated with hemodynamic instability. (Level
of Evidence: B)
3. Intravenous procainamide or ibutilide is rec-
ommended to restore sinus rhythm in pa-
tients with WPW in whom AF occurs without
hemodynamic instability in association with a
wide QRS complex on the electrocardiogram
(ECG) (greater than or equal to 120-ms du-
ration) or with a rapid preexcited ventricular
response. (Level of Evidence: C)
Class IIa
Intravenous flecainide or direct-current cardio-
version is reasonable when very rapid ventricu-
lar rates occur in patients with AF involving
conduction over an accessory pathway. (Level of
Evidence: B)
Class IIb
It may be reasonable to administer intravenous
quinidine, procainamide, disopyramide, ibutil-
ide, or amiodarone to hemodynamically stable
patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
Class III
Intravenous administration of digitalis glyco-
sides or nondihydropyridine calcium channel
antagonists is not recommended in patients with
WPW syndrome who have preexcited ventricu-
lar activation during AF. (Level of Evidence: B)
d. Hyperthyroidism
Class I
1. Administration of a beta blocker is recom-
mended to control the rate of ventricular
response in patients with AF complicating
thyrotoxicosis, unless contraindicated. (Level
of Evidence: B)
2. In circumstances when a beta blocker cannot
be used, administration of a nondihydropyr-
idine calcium channel antagonist (diltiazem
or verapamil) is recommended to control the
ventricular rate in patients with AF and
thyrotoxicosis. (Level of Evidence: B)
3. In patients with AF associated with thyrotox-
icosis, oral anticoagulation (INR 2.0 to 3.0) is
recommended to prevent thromboembolism,
as recommended for AF patients with other
risk factors for stroke. (Level of Evidence: C)
4. Once a euthyroid state is restored, recom-
mendations for antithrombotic prophylaxis
are the same as for patients without hyper-
thyroidism. (Level of Evidence: C)
e. Management of Atrial Fibrillation During Pregnancy
Class I
1. Digoxin, a beta blocker, or a nondihydropyr-
idine calcium channel antagonist is recom-
mended to control the rate of ventricular
response in pregnant patients with AF. (Level
of Evidence: C)
2. Direct-current cardioversion is recom-
mended in pregnant patients who become
hemodynamically unstable due to AF. (Level
of Evidence: C)
3. Protection against thromboembolism is rec-
ommended throughout pregnancy for all pa-
tients with AF (except those with lone AF
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and/or low thromboembolic risk). Therapy
(anticoagulant or aspirin) should be chosen
according to the stage of pregnancy. (Level of
Evidence: C)
Class IIb
1. Administration of heparin may be consid-
ered during the first trimester and last
month of pregnancy for patients with AF
and risk factors for thromboembolism. Un-
fractionated heparin may be administered
either by continuous intravenous infusion
in a dose sufficient to prolong the activated
partial thromboplastin time to 1.5 to 2
times the control value or by intermittent
subcutaneous injection in a dose of 10 000
to 20 000 units every 12 h, adjusted to
prolong the mid-interval (6 h after injec-
tion) activated partial thromboplastin time
to 1.5 times control. (Level of Evidence: B)
2. Despite the limited data available, subcuta-
neous administration of low-molecular-
weight heparin may be considered during
the first trimester and last month of preg-
nancy for patients with AF and risk factors
for thromboembolism. (Level of Evidence:
C)
3. Administration of an oral anticoagulant may
be considered during the second trimester for
pregnant patients with AF at high thrombo-
embolic risk. (Level of Evidence: C)
4. Administration of quinidine or procainamide
may be considered to achieve pharmacologi-
cal cardioversion in hemodynamically stable
patients who develop AF during pregnancy.
(Level of Evidence: C)
f. Management of Atrial Fibrillation in Patients With
Hypertrophic Cardiomyopathy (HCM)
Class I
Oral anticoagulation (INR 2.0 to 3.0) is recom-
mended in patients with HCM who develop AF,
as for other patients at high risk of thromboem-
bolism. (Level of Evidence: B)
Class IIa
Antiarrhythmic medications can be useful to
prevent recurrent AF in patients with HCM.
Available data are insufficient to recommend
one agent over another in this situation, but (a)
disopyramide combined with a beta blocker or
nondihydropyridine calcium channel antagonist
or (b) amiodarone alone is generally preferred.
(Level of Evidence: C)
g. Management of Atrial Fibrillation in Patients With
Pulmonary Disease
Class I
1. Correction of hypoxemia and acidosis is the
recommended primary therapeutic measure
for patients who develop AF during an acute
pulmonary illness or exacerbation of chronic
pulmonary disease. (Level of Evidence: C)
2. A nondihydropyridine calcium channel an-
tagonist (diltiazem or verapamil) is recom-
mended to control the ventricular rate in
patients with obstructive pulmonary dis-
ease who develop AF. (Level of Evidence: C)
3. Direct-current cardioversion should be at-
tempted in patients with pulmonary disease
who become hemodynamically unstable as
a consequence of AF. (Level of Evidence: C)
Class III
1. Theophylline and beta-adrenergic agonist
agents are not recommended in patients with
bronchospastic lung disease who develop AF.
(Level of Evidence: C)
2. Beta blockers, sotalol, propafenone, and
adenosine are not recommended in patients
with obstructive lung disease who develop
AF. (Level of Evidence: C)
II. Definition
A. Atrial Fibrillation
AF is a supraventricular tachyarrhythmia characterized by
uncoordinated atrial activation with consequent deteriora-
tion of mechanical function. On the ECG, rapid oscilla-
tions, or fibrillatory waves that vary in amplitude, shape,
and timing, replace consistent P waves, and there is an
irregular ventricular response that is rapid when conduc-
tion is intact (1). The ventricular response depends on
electrophysiological properties of the AV node and other
conducting tissues, vagal and sympathetic tone, the pres-
ence or absence of accessory pathways, and the action of
drugs (2). When AV block or ventricular or AV junctional
tachycardia is present, the cardiac cycles (R-R intervals)
may be regular. In patients with pacemakers, diagnosis of
AF may require pacemaker inhibition to expose fibrillatory
activity. An irregular, sustained, wide-QRS-complex
tachycardia suggests AF with conduction over an acces-
sory pathway or AF with bundle-branch block. Atrial
flutter is usually readily distinguished from AF. Extremely
rapid rates (greater than 200 beats per minute) suggest an
accessory pathway or ventricular tachycardia.
B. Related Arrhythmias
AF may occur in association with atrial flutter or atrial
tachycardia. The typical form of atrial flutter is characterized
by a saw-tooth pattern of regular atrial activation called
flutter (ƒ) waves on the ECG, particularly visible in leads II,
III, aVF, and V1. If untreated, the atrial rate typically ranges
from 240 to 320 beats per minute, with ƒ waves inverted in
ECG leads II, III, and aVF and upright in lead V1. The
direction of activation in the right atrium (RA) may be
reversed, resulting in upright ƒ waves in leads II, III, and aVF
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and inversion in lead V1. Atrial flutter may degenerate into
AF, and AF may convert to atrial flutter. Atrial flutter is
usually readily distinguished from AF, but misdiagnosis may
occur when fibrillatory atrial activity is prominent in more
than 1 ECG lead (3).
Focal atrial tachycardias, AV reentrant tachycardias, and
AV nodal reentrant tachycardias may also trigger AF. In these
tachycardias, distinct P waves are typically separated by an
isoelectric baseline, and their morphology may localize the
origin of the arrhythmia.
III. Classification
Various classification systems have been proposed for AF
based on the ECG pattern (1), epicardial (4) or endocavitary
recordings, mapping of atrial electrical activity, or clinical
features. Although the pattern of AF can change over time, it
may be helpful to characterize the arrhythmia at a given
moment. The classification scheme recommended here rep-
resents a consensus driven by a desire for simplicity and
clinical relevance.
The clinician should distinguish a first-detected episode of
AF, whether or not symptomatic or self-limited, recognizing
the uncertainty about the actual duration of the episode and
about previous undetected episodes (Fig. 1). After 2 or more
episodes, AF is considered recurrent. If the arrhythmia
terminates spontaneously, recurrent AF is designated parox-
ysmal; when sustained beyond 7 d, it is termed persistent.
Termination with pharmacological therapy or direct-current
cardioversion does not alter the designation. First-detected
AF may be either paroxysmal or persistent. The category of
persistent AF also includes cases of long-standing AF (e.g.,
longer than 1 y), usually leading to permanent AF, in which
cardioversion has failed or has been foregone.
These categories are not mutually exclusive, and a partic-
ular patient may have several episodes of paroxysmal AF and
occasional persistent AF, or the reverse, but it is practical to
categorize a given patient by his or her most frequent
presentation. The definition of permanent AF is often arbi-
trary, and the duration refers both to individual episodes and
to how long the diagnosis has been present in a given patient.
Thus, in a patient with paroxysmal AF, episodes lasting
seconds to hours may occur repeatedly for years.
This terminology applies to episodes lasting longer than
30 s without a reversible cause. Secondary AF in the setting
of acute MI, cardiac surgery, pericarditis, myocarditis, hyper-
thyroidism, or acute pulmonary disease is considered sepa-
rately. In these situations, AF is not the primary problem, and
concurrent treatment of the underlying disorder usually ter-
minates the arrhythmia. Conversely, when AF occurs in the
course of a concurrent disorder like well-controlled hypothy-
roidism, the general principles for management of the ar-
rhythmia apply.
The term lone AF applies to individuals younger than 60 y
without clinical or echocardiographic evidence of cardiopul-
monary disease, including hypertension (5). These patients
have a favorable prognosis with respect to thromboembolism
and mortality. Over time, patients move out of the lone AF
category due to aging or development of cardiac abnormali-
ties such as enlargement of the LA, and the risks of throm-
boembolism and mortality rise. The term nonvalvular AF
refers to cases without rheumatic mitral valve disease, pros-
thetic heart valve, or valve repair.
IV. Epidemiology and Prognosis
AF is the most common arrhythmia in clinical practice,
accounting for approximately one third of hospitalizations for
cardiac rhythm disturbances. An estimated 2.3 million people
in North America and 4.5 million people in the European
Union have paroxysmal or persistent AF (9). During the past
20 y, hospital admissions for AF have increased by 66% (7)
due to the aging of the population, a rising prevalence of
chronic heart disease, more frequent diagnosis through use of
ambulatory monitoring devices, and other factors. AF is an
extremely expensive public health problem (approximately
€3000 [approximately U.S. $3600] annually per patient) (8);
the total cost burden approaches €13.5 billion (approximately
U.S. $15.7 billion) in the European Union.
Figure 1. Patterns of atrial fibrillation (AF). 1,
Episodes that generally last 7 d or less (most
less than 24 h); 2, episodes that usually last
more than 7 d; 3, cardioversion failed or not
attempted; and 4, both paroxysmal and persis-
tent AF may be recurrent.
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A. Prevalence
The estimated prevalence of AF is 0.4% to 1% in the general
population (9), increasing with age to 8% in those older than
80 y (10). Among men, the age-adjusted prevalence has more
than doubled over a generation (10), while the prevalence in
women has remained constant (11). The median age of patients
with AF is about 75 y. The number of men and women with AF
is about equal, but approximately 60% of those over 75 y old are
female. Based on limited data, the age-adjusted risk of develop-
ing AF in blacks seems less than half that in whites.
In population-based studies, patients with no history of
cardiopulmonary disease account for fewer than 12% of all
cases of AF (10). In case series, however, the observed
proportion of lone AF was sometimes greater than 30% (12).
B. Incidence
In prospective studies, the incidence of AF increases from
less than 0.1% per year in people younger than 40 y to over
1.5% per year among women and 2% among men older than
80 y (13). In patients treated for HF, the 3-y incidence of AF
was almost 10% (14). Angiotensin inhibition may be associ-
ated with a reduced incidence of AF in patients with HF (15)
and hypertension (16).
C. Prognosis
AF is associated with an increased long-term risk of stroke (17),
HF, and all-cause mortality, especially among women (18). The
mortality rate of patients with AF is about double that of patients
in normal sinus rhythm and is linked to the severity of underly-
ing heart disease (19). In the Etude en Activité Libérale sur la
Fibrillation Auriculaire Study (ALFA), about two thirds of the
5% annualized mortality was attributed to cardiovascular causes
(12). In large HF trials (COMET [Carvedilol Or Metoprolol
European Trial], Val-HeFT [Valsartan Heart Failure Trial]), AF
was a strong independent risk factor for mortality and morbidity
(20,21). HF promotes AF, AF aggravates HF, and individuals
with either condition who develop the alternate condition share
a poor prognosis (22). Thus, managing patients with the associ-
ated conditions is a major challenge, and randomized trials are
needed to investigate the impact of AF on prognosis in HF.
The rate of ischemic stroke among patients with nonval-
vular AF averages 5% per year, 2 to 7 times that of people
without AF (23). One of every 6 strokes occurs in a patient
with AF, and when TIAs and clinically “silent” strokes
detected by brain imaging are considered, the rate of brain
ischemia accompanying nonvalvular AF exceeds 7% per year
(24). In patients with rheumatic heart disease and AF in the
Framingham Heart Study, stroke risk was increased 17-fold
compared with age-matched controls (25), and attributable
risk was 5 times greater than in those with nonrheumatic AF
(23). The risk of stroke increased with age; the annual risk of
stroke attributable to AF was 1.5% in participants aged 50 to
59 y and 23.5% in those aged 80 to 89 y (23).
V. Pathophysiological Mechanisms
A. Atrial Factors
1. Atrial Pathology as a Cause of Atrial Fibrillation
The most frequent histopathological changes in AF are atrial
fibrosis and loss of atrial muscle mass, but it is difficult to
distinguish changes due to AF from those due to associated heart
disease. Atrial fibrosis may precede the onset of AF (26), and
juxtaposition of patchy fibrosis with normal atrial fibers may
account for nonhomogeneity of conduction (27). Interstitial
fibrosis may result from apoptosis leading to replacement of
atrial myocytes (28), loss of myofibrils, accumulation of glyco-
gen granules, disruption of cell coupling at gap junctions (29),
and organelle aggregates (30) and may be triggered by atrial
dilation in any type of heart disease associated with AF.
Patients with valvular heart disease who have mild fibrosis
respond more successfully to cardioversion than those with
severe fibrosis, and fibrosis is thought to contribute to
persistent AF (31). The concentration of membrane-bound
glycoproteins that regulate cell–cell and cell–matrix interac-
tions (disintegrin and metalloproteinases) in human atrial
myocardium has been reported to double during AF, and
these changes may contribute to atrial dilation in patients with
longstanding AF. Dilation of the atria activates several
molecular pathways, including the renin-angiotensin-aldoste-
rone system (RAAS). Angiotensin II is upregulated in re-
sponse to stretch (32), and atrial tissue from patients with
persistent AF demonstrates increased expression of angioten-
sin-converting enzyme (ACE) (33). Angiotensin inhibition
may prevent AF by reducing fibrosis (34). Atrial dilation and
interstitial fibrosis in HF facilitate sustained AF (35). The
regional electrical silence (suggesting scar), voltage reduc-
tion, and conduction slowing described in patients with HF
are similar to changes in the atria that occur as a consequence
of aging (36).
2. Mechanisms of Atrial Fibrillation
Available data support a “focal” triggering mechanism involving
automaticity or multiple reentrant wavelets, but these mecha-
nisms are not mutually exclusive and may coexist (Fig. 2).
The important observation that a focal source for AF could
be identified and ablation of this source could extinguish AF
(37) supported a focal origin. While pulmonary veins (PVs)
are the most frequent source of these rapidly atrial impulses,
Figure 2. Posterior view of principal electrophysiological mecha-
nisms of atrial fibrillation. A, Focal activation. The initiating focus
(indicated by the star) often lies within the region of the pulmo-
nary veins. The resulting wavelets represent fibrillatory conduc-
tion, as in multiple-wavelet reentry. B, Multiple-wavelet reentry.
Wavelets (indicated by arrows) randomly re-enter tissue previ-
ously activated by the same or another wavelet. The routes the
wavelets travel vary. Reproduced with permission from Konings
KT, Kirchhof CJ, Smeets JR, et al. High-density mapping of
electrically induced atrial fibrillation in humans. Circulation
1994;89:1665–1680 (45). LA indicates left atrium; PV, pulmonary
vein; ICV, inferior vena cava; SCV, superior vena cava; and RA,
right atrium.
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foci have also been found in the superior vena cava, ligament
of Marshall, left posterior free wall, crista terminalis, and
coronary sinus (37– 40). In histological studies, cardiac mus-
cle with preserved electrical properties extends into the PVs
(41), and the primacy of PVs as triggers of AF has prompted
substantial research into the anatomical and electrophysiolog-
ical properties of these structures. Atrial tissue in the PVs of
patients with AF has shorter refractory periods than in control
patients or other parts of the atria in patients with AF (42,43).
This heterogeneity of conduction may promote reentry and
form a substrate for sustained AF (44).
The multiple-wavelet hypothesis as the mechanism of
reentrant AF (46) involves fractionation of wave fronts
propagating through the atria and self-perpetuating “daughter
wavelets.” In this model, the number of wavelets at any time
depends on the refractory period, mass, and conduction
velocity in different parts of the atria. A large atrial mass with
a short refractory period and delayed conduction increases the
number of wavelets, favoring sustained AF. Simultaneous
recordings from multiple electrodes supported the multiple-
wavelet hypothesis in human subjects (47). Although the
multiple-wavelet hypothesis was for years the dominant
theory explaining the mechanism of AF, data from experi-
mental (47a) and clinical (47b,47c) mapping studies chal-
lenge this notion. In patients with idiopathic paroxysmal AF,
widespread distribution of abnormal electrograms in the RA
predicts development of persistent AF (48), suggesting the
importance of an abnormal substrate in the maintenance of
AF. Furthermore, in patients with persistent AF undergoing
conversion to sinus rhythm, intra-atrial conduction is pro-
longed compared with a control group, especially among
those who develop recurrent AF (49). Among patients with
HF, prolongation of the P wave on signal-averaged ECG
analysis was more frequent in those prone to paroxysmal AF
(50). Because many of these observations were made prior to
onset of clinical AF, the findings cannot be ascribed to atrial
remodeling that occurs as a consequence of AF, and the
degree to which changes in the atrial architecture contribute
to the initiation and maintenance of AF is not known.
3. Atrial Electrical Remodeling
Pharmacological or direct-current cardioversion of AF has a
higher success rate when AF has been present for less than
24 h (51), whereas more prolonged AF makes restoring and
maintaining sinus rhythm less likely. These observations gave
rise to the adage “atrial fibrillation begets atrial fibrillation.”
The notion that AF is self-perpetuating takes experimental
support from a goat model using an automatic atrial fibrillator
that detected spontaneous termination of AF and reinduced
the arrhythmia by electrical stimulation (52). Initially, elec-
trically induced AF terminated spontaneously. After repeated
inductions, however, the episodes became progressively more
sustained until AF persisted at a more rapid atrial rate (52).
The increasing propensity to AF was related to progressive
shortening of effective refractory periods with increasing
episode duration, a phenomenon known as electrophysiolog-
ical remodeling.
In addition to remodeling and changes in electrical refrac-
toriness, prolonged AF disturbs atrial contractile function.
After a period of persistent AF, recovery of atrial contraction
can be delayed for days or weeks following the restoration of
sinus rhythm, and this has important implications for the
duration of anticoagulation after cardioversion. (See Section
VIII.B.2, Preventing Thromboembolism.)
4. Other Factors Contributing to Atrial Fibrillation
Data are accumulating on the importance of the RAAS in the
genesis of AF (53). Irbesartan plus amiodarone was associ-
ated with a lower incidence of recurrent AF after cardiover-
sion than amiodarone alone (15), and treatment with angio-
tensin inhibitors and diuretics reduced the incidence of AF
after catheter ablation of atrial flutter (54). Inhibition of the
RAAS, alone or in combination with other therapies, may
prevent the onset or maintenance of AF through several
mechanisms (55), including lower atrial pressure and wall
stress, prevention of structural remodeling (fibrosis, dilation,
and hypertrophy) in both the LA and left ventricle (LV),
inhibition of neurohumoral activation, reducing blood pres-
sure, prevention or amelioration of HF, and avoidance of
hypokalemia. Treatment with trandolapril reduced the inci-
dence of AF in patients with LV dysfunction following acute
MI (56), but it remains to be clarified whether this effect is
related to reversal of structural or electrical remodeling in the
atria or to another mechanism.
Other factors potentially involved in the induction or
maintenance of AF are outlined in Table 2. Among these is
inflammation, and ongoing studies are exploring the use of
statin-type lipid-lowering drugs with this mechanism in mind.
B. Atrioventricular Conduction
1. General Aspects
In the absence of an accessory pathway or His-Purkinje
dysfunction, the AV node limits conduction during AF (57).
Of the multiple atrial inputs to the AV node that have been
identified, 2 seem dominant: one directed posteriorly via the
crista terminalis and the other aimed anteriorly via the
interatrial septum. Other factors affecting AV conduction are
the intrinsic refractoriness of the AV node, concealed con-
duction, and autonomic tone. Concealed conduction plays a
prominent role in determining the ventricular response during
AF (58) by altering the refractoriness of the AV node and
slowing or blocking atrial impulses and may explain the
irregularity of ventricular response during AF (59). When the
atrial rate is relatively slow during AF, the ventricular rate
tends to rise and, conversely, higher atrial rate is associated
with slower ventricular rate.
Increased parasympathetic and reduced sympathetic tone
exert negative dromotropic effects on AV nodal conduction,
while the opposite is true in states of decreased parasympa-
thetic and increased sympathetic tone (58). Vagal tone also
enhances the negative chronotropic effects of concealed
conduction in the AV node (60). Fluctuations in autonomic
tone can produce disparate ventricular responses to AF,
exemplified by a slow ventricular rate during sleep but
accelerated ventricular response during exercise. Digitalis,
which slows the ventricular rate during AF predominantly by
increasing vagal tone, is more effective for controlling heart
rate at rest in AF but less effective during activity.
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2. Atrioventricular Conduction in
Preexcitation Syndromes
Conduction across an accessory pathway during AF can
result in dangerously rapid ventricular rates (2). Transition of
AV reentry into AF in patients with the WPW syndrome can
produce a rapid ventricular response that degenerates into
lethal ventricular fibrillation (61). Drugs that lengthen refrac-
toriness and slow conduction across the AV node (such as
digitalis, verapamil, or diltiazem) do not block conduction
over the accessory pathway and may accelerate the ventric-
ular rate. Hence, these agents are contraindicated in this
situation (62). Although the potential for beta blockers to
potentiate conduction across the accessory pathway is con-
troversial, caution should be exercised in the use of these
agents as well in patients with AF associated with
preexcitation.
C. Myocardial and Hemodynamic Consequences of
Atrial Fibrillation
Among factors that affect hemodynamic function during AF
are loss of synchronous atrial mechanical activity, irregular
ventricular response, rapid heart rate, and impaired coronary
arterial blood flow. Loss of atrial contraction may markedly
decrease cardiac output, especially when diastolic ventricular
filling is impaired by mitral stenosis, hypertension, HCM, or
restrictive cardiomyopathy. Myocardial contractility is not
constant during AF because of force–interval relationships
associated with variations in cycle length (63). In patients
with persistent AF, mean LA and RA volumes increase over
time (64) and restoration and maintenance of sinus rhythm
decrease these volumes (65). Moreover, TEE has demon-
strated that contractile function and blood flow velocity in the
LAA recover after cardioversion, consistent with a reversible
atrial cardiomyopathy in patients with AF (66). Although one
might expect restoration of sinus rhythm to improve the other
hemodynamic characteristics associated with AF, this is not
always the case (67).
Beyond its effects on atrial function, a persistently elevated
ventricular rate during AF may adversely increase mitral
regurgitation and produce dilated ventricular cardiomyopathy
(tachycardia-induced cardiomyopathy) (2,68). It is important
to recognize this cause of cardiomyopathy, in which HF is a
consequence rather than the cause of AF, because control of
the ventricular rate may lead to reversal of the myopathic
process. A variety of hypotheses have been proposed to
explain tachycardia-mediated cardiomyopathy on the basis of
myocardial energy depletion, ischemia, abnormal calcium
regulation, and remodeling, but the actual mechanisms are
still unclear (69).
D. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism of thrombus from the
LA, the pathogenesis of thromboembolism is complex (70).
Up to 25% of strokes in patients with AF may be due to
intrinsic cerebrovascular diseases, other cardiac sources of
embolism, or atheromatous pathology in the proximal aorta
(71,72). The annual risk of stroke in patients with AF is in the
range of 3% to 8% per year, depending on associated stroke
risk factors (23). About half of all elderly AF patients have
hypertension (a major risk factor for cerebrovascular disease),
and approximately 12% have carotid artery stenosis (73).
Carotid atherosclerosis is not substantially more prevalent in
AF patients with stroke than in patients without AF, however,
and is probably a relatively minor contributing epidemiolog-
ical factor (74).
1. Pathophysiology of Thrombus Formation
Thrombus formation as a result of stasis in the LAA is
thought to represent the main source of disabling cardioem-
bolic ischemic strokes in patients with AF. These thrombi
cannot be regularly examined by precordial (transthoracic)
echocardiography (75), and TEE is a more sensitive and
specific method to assess LAA function (76) and detect
thrombus formation. Serial TEE studies of the LA (77) and
LAA (78) during conversion of AF to sinus rhythm demon-
TABLE 2. Etiologies and Factors Predisposing Patients to AF
Electrophysiological abnormalities
Enhanced automaticity (focal AF)
Conduction abnormality (reentry)
Atrial pressure elevation
Mitral or tricuspid valve disease
Myocardial disease (primary or secondary, leading to systolic or diastolic
dysfunction)
Semilunar valvular abnormalities (causing ventricular hypertrophy)
Systemic or pulmonary hypertension (pulmonary embolism)
Intracardiac tumors or thrombi
Atrial ischemia
Coronary artery disease
Inflammatory or infiltrative atrial disease
Pericarditis
Amyloidosis
Myocarditis
Age-induced atrial fibrotic changes
Drugs
Alcohol
Caffeine
Endocrine disorders
Hyperthyroidism
Pheochromocytoma
Changes in autonomic tone
Increased parasympathetic activity
Increased sympathetic activity
Primary or metastatic disease in or adjacent to the atrial wall
Postoperative
Cardiac, pulmonary, or esophageal
Congenital heart disease
Neurogenic
Subarachnoid hemorrhage
Nonhemorrhagic, major stroke
Idiopathic (lone AF)
Familial AF
AF indicates atrial fibrillation.
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strated reduced LAA flow velocities related to loss of
organized mechanical contraction during AF. Thrombi are
more often encountered in AF patients with ischemic stroke
than in those without stroke (79). Although clinical manage-
ment is based on the presumption that thrombus formation
requires continuation of AF for approximately 48 h, thrombi
have been identified by TEE within shorter intervals (80,81).
After successful cardioversion, regardless of whether the
method is electrical, pharmacological, or spontaneous (82),
stunning of the LAA may account for an increased risk of
thromboembolic events. Atrial stunning is at a maximum
immediately after cardioversion; progressive improvement of
atrial transport function usually occurs within a few days but
sometimes takes as long as 3 to 4 wk, depending on the
duration of AF (82,83). This corroborates the clinical obser-
vation that following cardioversion, more than 80% of
thromboembolic events occur during the first 3 d and almost
all occur within 10 d (84). TEE studies have verified
resolution of thrombus in the majority of patients (85).
Similar observations have defined the dynamic nature of
LA/LAA dysfunction following conversion of AF, providing
a mechanistic rationale for anticoagulation for several weeks
before and after successful cardioversion. Although stunning
may be milder with certain associated conditions or a short
duration of AF, anticoagulation is recommended during
cardioversion and for at least 4 wk afterward in all patients
with AF lasting longer than 48 h or of unknown duration,
including lone AF, except when contraindicated.
Decreased flow within the LA/LAA during AF has been
associated with spontaneous echo contrast (SEC), thrombus
formation, and embolic events (86,87). Specifically, SEC, or
“smoke,” a swirling haze of variable density, may be detected
by transthoracic echocardiography or TEE imaging under
low-flow conditions (88). There is evidence that SEC is a
marker of stasis caused by AF (89,90), but the utility of SEC
for prospective thromboembolic risk stratification beyond
that achieved by clinical assessment alone has not been
confirmed.
LAA flow velocities are lower in patients with atrial flutter
than is usually seen during sinus rhythm but higher than in
AF. Whether this accounts for any lower prevalence of LAA
thrombus or thromboembolism associated with atrial flutter is
uncertain. As in AF, atrial flutter is associated with low
appendage emptying velocities following cardioversion with
the potential for thromboembolism (91) and anticoagulation
is recommended similarly. (See Section 8.1.4.1.3 in the
full-text guidelines, Therapeutic Implications.)
2. Clinical Implications
Complex thromboembolic mechanisms are operative in AF
and involve the interplay of risk factors related to atrial stasis,
endothelial dysfunction, and systemic and possibly local
hypercoagulability. The strong association between hyperten-
sion and stroke in AF is probably mediated primarily by
embolism originating in the LAA (72), but hypertension also
increases the risk of noncardioembolic strokes in patients
with AF (92). Whether control of hypertension lowers the risk
for cardioembolic stroke in patients with AF is a vital
question.
The increasing stroke risk in patients with AF with advanc-
ing age is also multifactorial. Aging is a risk factor for
atherosclerosis, and plaques in the aortic arch are associated
with stroke independent of AF (93). Age is a more potent risk
factor when combined with other risk factors such as hyper-
tension or female gender, and women over age 75 y with AF
are at particular risk for stroke (94).
LV systolic dysfunction, as indicated by a history of HF or
echocardiographic assessment, predicts ischemic stroke in pa-
tients with AF who receive no antithrombotic therapy (95) but
not in moderate-risk patients given aspirin (96,97). LV systolic
dysfunction has been associated both with LA thrombus and
with noncardioembolic strokes in patients with AF (72,98).
VI. Causes, Associated Conditions, Clinical
Manifestations, and Quality of Life
A. Causes and Associated Conditions
1. Reversible Causes of Atrial Fibrillation
AF may be related to acute temporary causes, including
alcohol intake (“holiday heart syndrome”), surgery, electro-
cution, MI, pericarditis, myocarditis, pulmonary embolism or
other pulmonary diseases, hyperthyroidism, and other meta-
bolic disorders. In such cases, successful treatment of the
underlying condition often eliminates AF. In the setting of
acute MI, the development of AF portends an adverse
prognosis compared with preinfarct AF or sinus rhythm
(99,100). When AF is associated with atrial flutter, WPW
syndrome, or AV nodal reentrant tachycardia, treatment of
the primary arrhythmia reduces or eliminates the incidence of
recurrent AF (101). AF is a common early postoperative
complication of cardiac and thoracic surgery.
2. Atrial Fibrillation Without Associated Heart Disease
Approximately 30% to 45% of cases of paroxysmal AF and
20% to 25% of cases of persistent AF occur in young patients
without demonstrable underlying disease (“lone AF”) (12).
AF can present as an isolated or familial arrhythmia, although
a causal underlying disease may appear over time (102).
Although AF may occur in the elderly without underlying
heart disease, the changes in cardiac structure and function
that accompany aging, such as increased myocardial stiffness,
may be associated with AF, just as heart disease in older
patients may be coincidental and unrelated to AF.
3. Medical Conditions Associated With Atrial Fibrillation
Obesity is an important risk factor for the development of AF
(103). After adjustment for clinical risk factors, the excess
risk of AF appears related to LA dilation. There is a graded
increase in LA size as body mass index increases from normal
to the overweight and obese categories, and weight has been
linked to regression of LA enlargement (104). These findings
suggest a physiological link between obesity, AF, and stroke
and raise the intriguing possibility that weight reduction may
decrease the risk associated with AF.
4. Atrial Fibrillation With Associated Heart Disease
Specific cardiovascular conditions associated with AF in-
clude valvular heart disease (most often mitral valve disease),
HF, coronary artery disease (CAD), and hypertension, partic-
ularly when LV hypertrophy (LVH) is present. In addition,
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AF may be associated with HCM, dilated cardiomyopathy, or
congenital heart disease, especially atrial septal defect in
adults. Potential etiologies also include restrictive cardiomy-
opathies (e.g., amyloidosis, hemochromatosis, and endomyo-
cardial fibrosis), cardiac tumors, and constrictive pericarditis.
Other heart diseases, such as mitral valve prolapse with or
without mitral regurgitation, calcification of the mitral annu-
lus, cor pulmonale, and idiopathic dilation of the RA, have
been associated with a high incidence of AF. AF is commonly
encountered in patients with sleep apnea syndrome, but
whether the arrhythmia is provoked by hypoxia, another
biochemical abnormality, changes in pulmonary dynamics or
RA factors, changes in autonomic tone, or systemic hyper-
tension has not been determined.
5. Familial Atrial Fibrillation
Familial AF, defined as lone AF running in a family, is more
common than previously recognized but should be distin-
guished from AF secondary to other genetic diseases like
familial cardiomyopathies. The likelihood of developing AF
is increased among the offspring of parents with AF, suggest-
ing a familial susceptibility to the arrhythmia, but the mech-
anisms associated with transmission are not necessarily elec-
trical, because the relationship has also been seen in patients
with a family history of hypertension, diabetes, or HF (105).
The molecular defects responsible for familial AF are largely
unknown. Specific chromosomal loci linked to AF in some
families (106) suggest distinct genetic mutations (107).
6. Autonomic Influences in Atrial Fibrillation
Autonomic influences play an important role in the initiation
of AF. Measurement of heart rate variability (HRV) reflects
changes in relative autonomic modulation rather than the
absolute level of sympathetic or parasympathetic tone. It
appears, however, that the balance between sympathetic and
vagal influences is important as a predictor of AF. Vagal
predominance has been observed in the minutes preceding the
onset of AF in some patients with structurally normal hearts,
while in others there is a shift toward sympathetic predomi-
nance (108,109). Although certain patients can be character-
ized in terms of a vagal or an adrenergic form of AF, these
cases likely represent the extremes of either influence (110).
In general, vagally mediated AF occurs at night or after
meals, while adrenergically induced AF typically occurs
during the daytime (111). In patients with vagally mediated
AF, the more common form, adrenergic blocking drugs or
digitalis sometimes worsen symptoms. For AF of the adren-
ergic type, beta blockers are the initial treatment of choice.
B. Clinical Manifestations
AF may cause a sensation of palpitations, have distinct
hemodynamic or thromboembolic consequences, or follow an
asymptomatic period of unknown duration. Ambulatory ECG
recordings and device-based monitoring reveal that individ-
uals may experience periods of both symptomatic and asymp-
tomatic AF (112–114). Over time, palpitation may disappear,
such that patients in whom the arrhythmia has become
permanent may become asymptomatic. This is particularly
common among the elderly. Some patients experience symp-
toms only during paroxysmal AF, or only intermittently
during sustained AF. When present, symptoms of AF vary
with the irregularity and rate of ventricular response, under-
lying functional status, duration of AF, and individual patient
factors (115).
The initial presentation of AF may be an embolic compli-
cation or exacerbation of HF, but most patients complain of
palpitations, chest pain, dyspnea, fatigue, lightheadedness, or
syncope. Polyuria may be associated with the release of atrial
natriuretic peptide, particularly as episodes of AF begin or
terminate. AF associated with a sustained, rapid ventricular
response can lead to tachycardia-mediated cardiomyopathy,
especially in patients unaware of the arrhythmia. Syncope is
an uncommon complication that can occur upon conversion
in patients with sinus node dysfunction or because of rapid
ventricular rates in patients with HCM, valvular aortic steno-
sis, or an accessory pathway.
C. Quality of Life
Available data suggest that quality of life is considerably
impaired in patients with AF compared to age-matched
controls. Sustained sinus rhythm is associated with improved
quality of life and better exercise performance than AF in
some studies but not others (116). In a typical study, a
majority of patients with paroxysmal AF considered the
arrhythmia disruptive of lifestyle, but this perception was not
associated with either the frequency or duration of symptom-
atic episodes (117).
VII. Clinical Evaluation
A. Basic Evaluation of the Patient With
Atrial Fibrillation
1. Clinical History and Physical Examination
The diagnosis of AF requires confirmation by ECG record-
ing, sometimes in the form of bedside telemetry or ambula-
tory Holter recordings. The initial evaluation of a patient with
suspected or proven AF involves characterizing the pattern of
the arrhythmia as paroxysmal or persistent, determining its
cause, and defining associated cardiac and extracardiac fac-
tors pertinent to the etiology, tolerability, and management.
The work-up and therapy can usually be accomplished in a
single outpatient encounter (Table 3), unless the rhythm has
not been specifically documented and additional monitoring
is necessary.
Physical examination may suggest AF on the basis of
irregular pulse, irregular jugular venous pulsations, variation
in the intensity of the first heart sound, or absence of a fourth
sound heard previously during sinus rhythm. The findings are
similar in patients with atrial flutter, except that the rhythm
may be regular and rapid venous oscillations may occasion-
ally be visible in the jugular pulse.
2. Investigations
The diagnosis of AF requires ECG documentation by at least
a single-lead recording during the arrhythmia. In patients with
implanted pacemakers or defibrillators, the diagnostic and
memory functions may allow accurate and automatic detec-
tion (118). A chest radiograph is valuable mostly to detect
intrinsic pulmonary pathology and evaluate the pulmonary
vasculature. It is important that thyroid, renal, and hepatic
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TABLE 3. Clinical Evaluation in Patients With AF
Minimum evaluation
1. History and physical examination, to define
Presence and nature of symptoms associated with AF
Clinical type of AF (first episode, paroxysmal, persistent, or permanent)
Onset of the first symptomatic attack or date of discovery of AF
Frequency, duration, precipitating factors, and modes of termination of AF
Response to any pharmacological agents that have been administered
Presence of any underlying heart disease or other reversible conditions (e.g., hyperthyroidism or alcohol consumption)
2. Electrocardiogram, to identify
Rhythm (verify AF)
LV hypertrophy
P-wave duration and morphology or fibrillatory waves
Preexcitation
Bundle-branch block
Prior MI
Other atrial arrhythmias
To measure and follow the R-R, QRS, and QT intervals in conjunction with antiarrhythmic drug therapy
3. Transthoracic echocardiogram, to identify
Valvular heart disease
LA and RA size
LV size and function
Peak RV pressure (pulmonary hypertension)
LV hypertrophy
LA thrombus (low sensitivity)
Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function
For a first episode of AF, when the ventricular rate is difficult to control
Additional testing
One or several tests may be necessary.
1. Six-minute walk test
If the adequacy of rate control is in question
2. Exercise testing
If the adequacy of rate control is in question (permanent AF)
To reproduce exercise-induced AF
To exclude ischemia before treatment of selected patients with a type IC antiarrhythmic drug
3. Holter monitoring or event recording
If diagnosis of the type of arrhythmia is in question
As a means of evaluating rate control
4. Transesophageal echocardiography
To identify LA thrombus (in the LA appendage)
To guide cardioversion
5. Electrophysiological study
To clarify the mechanism of wide-QRS-complex tachycardia
To identify a predisposing arrhythmia such as atrial flutter or paroxysmal supraventricular tachycardia
To seek sites for curative ablation or AV conduction block/modification
6. Chest radiograph, to evaluate
Lung parenchyma, when clinical findings suggest an abnormality
Pulmonary vasculature, when clinical findings suggest an abnormality
Type IC refers to the Vaughan Williams classification of antiarrhythmic drugs (see Table 14).
AF indicates atrial fibrillation; AV, atrioventricular; LA, left atrial; LV, left ventricular; MI, myocardial infarction; RA, right atrial; and
RV, right ventricular.
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functions, serum electrolytes, and the hemogram be measured
at least once in the course of evaluation (119). All patients
with AF should also have 2-dimensional, Doppler echocar-
diography to assess LA and LV dimensions, LV wall thick-
ness, and function and to exclude occult valvular or pericar-
dial disease and HCM. Thrombus in the LA or LAA is
seldom detected without TEE. Among the TEE features
associated with thromboembolism in patients with nonvalvu-
lar AF are thrombus, SEC, reduced LAA flow velocity, and
aortic atheromatous abnormalities (120), but prospective
investigations are needed to compare these TEE findings with
clinical and transthoracic echocardiographic predictors of
thromboembolism. Detection of LA/LAA thrombus in the
setting of stroke or systemic embolism is convincing evi-
dence of a cardiogenic mechanism (81).
VIII. Management
A. Strategic Objectives
Management of patients with AF involves 3 objectives—rate
control, prevention of thromboembolism, and correction of
the rhythm disturbance—and these are not mutually exclu-
sive. The initial management decision involves primarily a
rate control or rhythm control strategy. Under the rate control
strategy, the ventricular rate is controlled with no commit-
ment to restore or maintain sinus rhythm. The rhythm control
strategy attempts restoration and/or maintenance of sinus
rhythm. The latter strategy also requires attention to rate
control. Depending on the patient’s course, the strategy
initially chosen may prove unsuccessful and the alternate
strategy is then adopted. Regardless of whether the rate
control or rhythm control strategy is pursued, attention must
also be directed to antithrombotic therapy for prevention of
thromboembolism.
B. Pharmacological and Nonpharmacological
Treatment Options
Drugs and ablation are effective for both rate and rhythm
control, and in special circumstances surgery may be the
preferred option. Regardless of the approach, the need for
anticoagulation is based on stroke risk and not on whether
sinus rhythm is maintained. For rhythm control, drugs are
typically the first choice and LA ablation is a second-line
choice, especially in patients with symptomatic lone AF. In
some patients, especially young persons with very symptom-
atic AF who need sinus rhythm, radiofrequency ablation may
be preferred over years of drug therapy. Patients with preop-
erative AF undergoing cardiac surgery face a unique oppor-
tunity. While few are candidates for a stand-alone surgical
procedure to cure AF using the maze or LA ablation tech-
niques, these approaches can be an effective adjunct to
coronary bypass or valve repair surgery to prevent recurrent
postoperative AF. Because the LAA is the site of greater than
95% of detected thrombi, this structure is commonly removed
from the circulation during cardiac surgery in patients at risk
of developing postoperative AF, although this has not been
proved to prevent stroke (121).
1. Heart Rate Control Versus Rhythm Control
For patients with symptomatic AF lasting many weeks, initial
therapy may be anticoagulation and rate control while the
long-term goal is to restore sinus rhythm. When cardioversion
is contemplated and the duration of AF is unknown or
exceeds 48 h, patients who do not require long-term antico-
agulation may benefit from short-term anticoagulation. If rate
control offers inadequate symptomatic relief, restoration of
sinus rhythm becomes a clear long-term goal. Early cardio-
version may be necessary if AF causes hypotension or
worsening HF. In contrast, amelioration of symptoms by rate
control in older patients may steer the clinician away from
attempts to restore sinus rhythm. In some circumstances,
when the initiating pathophysiology of AF is reversible, as for
instance in the setting of thyrotoxicosis or after cardiac
surgery, no long-term therapy may be necessary.
Randomized trials comparing outcomes of rhythm versus
rate control strategies in patients with AF are summarized in
Tables 4, 5, and 6. Among these, AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) found no
difference in mortality or stroke rate between patients as-
signed to one strategy or the other. The RACE (Rate Control
vs. Electrical cardioversion for persistent atrial fibrillation)
trial found rate control not inferior to rhythm control for
prevention of death and morbidity. Clinically silent recur-
rences of AF in asymptomatic patients treated with antiar-
TABLE 4. Trials Comparing Rate Control and Rhythm Control Strategies in Patients With AF
Clinical Events (n)
Stroke/Embolism Death
Trial Reference Patients (n) AF Duration
Follow-Up
(y)
Age (mean
y SD) Patients in SR* Rate Rhythm Rate Rhythm
AFFIRM (2002) 128 4060 †/NR 3.5 709 35% vs. 63% (at 5 y) 88/2027 93/2033 310/2027 356/2033
RACE (2002) 124 522 1 to 399 d 2.3 689 10% vs. 39% (at 2.3 y) 7/256 16/266 18/256 18/266
PIAF (2000) 130 252 7 to 360 d 1 6110 10% vs. 56% (at 1 y) 0/125 2/127 2/125 2/127
STAF (2003) 126 200 63 mo 1.6 668 11% vs. 26% (at 2 y) 2/100 5/100 8/100 4/100
HOT CAFÉ (2004) 127 205 7 to 730 d 1.7 6111 NR vs. 64% 1/101 3/104 1/101 3/104
*Comparison between rate and rhythm control groups.
†Approximately one third of patients were enrolled with first episode of atrial fibrillation (AF).
AFFIRM indicates Atrial Fibrillation Follow-Up Investigation of Rhythm Management; ECV, internal or external electrical cardioversion; HOT CAFE´, How to Treat
Chronic Atrial Fibrillation; IA, quinidine, procainamide; IC, propafenone and/or flecainide; NR, not reported; PIAF, Pharmacological Intervention in Atrial Fibrillation;
RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; SR, sinus rhythm; STAF, Strategies of Treatment of Atrial Fibrillation; and TE,
thromboembolism.
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rhythmic drugs may be responsible for thromboembolic
events after withdrawal of anticoagulation. Hence, patients at
high risk for stroke may require anticoagulation regardless of
whether the rate control or rhythm control strategy is chosen,
but the AFFIRM trial was not designed to address this
question (122). While secondary analyses support this notion,
the stroke rate in patients assigned to rhythm control who
stopped warfarin is uncertain, and additional research is
needed to address this important question.
Information about the effects of antiarrhythmic and chrono-
tropic therapies on quality of life is inconsistent (116,130,131).
Neither the AFFIRM (132), RACE (124), PIAF (Pharmacologic
Intervention in Atrial Fibrillation) (125), nor STAF (Strategies
of Treatment of Atrial Fibrillation) (126) studies found differ-
ences in quality of life with rhythm control compared with rate
control. Rhythm control in the PIAF and HOT CAFÉ (How to
Treat Chronic Atrial Fibrillation) (127) studies resulted in better
exercise tolerance than rate control, but this did not translate into
improved quality of life. Symptomatic improvement has been
reported after the maze procedure in patients with AF (133).
Clinicians must exercise judgment, however, in translating shifts
in quality of life in these selected populations to the sense of
well-being experienced by individual patients. Patients with
similar health status may experience an entirely different quality
of life, and treatment must be tailored to each individual,
depending on the nature, intensity, and frequency of symptoms,
patient preferences, comorbid conditions, and the ongoing re-
sponse to treatment.
Depending on symptoms, rate control may be reasonable
initial therapy in older patients with persistent AF who have
hypertension or heart disease. For younger individuals, espe-
cially those with paroxysmal lone AF, rhythm control may be
a better initial approach. Often, medications that exert both
antiarrhythmic and rate-controlling effects are required. Cath-
eter ablation should be considered to maintain sinus rhythm
in selected patients who failed to respond to antiarrhythmic
drug therapy (134).
In patients with AF, the ventricular rate may accelerate
excessively during exercise even when it is well-controlled at
rest. In addition to allowing adequate time for ventricular
filling and avoiding rate-related ischemia, enhancement of
intraventricular conduction with rate reduction may result in
TABLE 5. General Characteristics of Rhythm Control and Rate Control Trials in Patients With AF
Patients Reaching Primary Endpoint (n)
Trial Reference
Patients
(n)
Mean
Age
(y)
Mean Length
of Follow-Up
(y)
Inclusion
Criteria
Primary
Endpoint
Rate
Control
Rhythm
Control p
PIAF (2000) 130 252 61.0 1.0 Persistent AF (7 to 360 d) Symptomatic improvement 76/125 (60.8%) 70/127 (55.1%) 0.317
RACE (2002) 124 522 68.0 2.3 Persistent AF or flutter for less than 1 y
and 1 to 2 cardioversions over 2 y and
oral anticoagulation
Composite: cardiovascular death, CHF,
severe bleeding, PM implantation,
thromboembolic events, severe adverse
effects of antiarrhythmic drugs
44/256 (17.2%) 60/266 (22.6%) 0.11
STAF (2002) 126 200 66.0 1.6 Persistent AF (longer than 4 wk and less
than 2 y), left atrial size greater than
45 mm, CHF NYHA II–IV, LVEF less than
45%
Composite: overall mortality,
cerebrovascular complications, CPR,
embolic events
10/100 (10.0%) 9/100 (9.0%) 0.99
AFFIRM
(2002)
128 4060 69.7 3.5 Paroxysmal AF or persistent AF, age 65 y
or older, or risk of stroke or death
All-cause mortality 310/2027 (25.9%) 356/2033 (26.7%) 0.08
HOT CAFÉ
(2004)
127 205 60.8 1.7 First clinically overt episode of persistent
AF (7 d or more and less than 2 y), 50 to
75 y old
Composite; death, thromboembolic
complications; intracranial or other major
hemorrhage
1/101 (1.0%) 4/104 (3.9%) Greater
than 0.71
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract
Cardiovasc Med 2005;2:514 –21 (129).
AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management, CHF, congestive heart failure; CPR, cardiopulmonary
resuscitation; HOT CAFE´, How to Treat Chronic Atrial Fibrillation; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PIAF, Pharmacological
Intervention in Atrial Fibrillation; PM, pacemaker; RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; and STAF, Strategies of Treatment
of Atrial Fibrillation.
TABLE 6. Comparison of Adverse Outcomes in Rhythm Control and Rate Control Trials in Patients With AF
Trial Reference
Deaths of All
Causes
(n rate/rhythm)
Deaths From
Cardiovascular
Causes
Deaths From
Noncardiovascular
Causes Stroke
Thromboembolic
Events Bleeding
RACE (2002) 124 36 18/18 ND ND 14/21 12/9
PIAF (2000) 130 4 1/1 1* ND ND ND
STAF (2003) 126 12 (8/4) 8/3 0/1 1/5 ND 8/11
AFFIRM (2002) 128 666 (310/356) 167/164 113/165 77/80 ND 107/96
HOT CAFÉ (2004) 127 4 (1/3) 0/2 1/1 0/3 ND 5/8
*Total number of patients not reported.
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial fibrillation. Nat Clin Pract
Cardiovasc Med 2005;2:514 –21 (129).
AF indicates atrial fibrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; HOT CAFE´, How to Treat Chronic Atrial Fibrillation; ND, not
determined; PIAF, Pharmacological Intervention in Atrial Fibrillation; RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; and STAF,
Strategies of Treatment of Atrial Fibrillation.
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improved hemodynamics. It may be useful to evaluate the heart
rate response to submaximal or maximal exercise or to monitor
the rate over an extended period (e.g., by use of 24-h Holter
recording). The definition of adequate rate control has been
based primarily on short-term hemodynamic benefits and not
well studied with respect to regularity or irregularity of the
ventricular response to AF, quality of life, symptoms, or devel-
opment of cardiomyopathy. No standard method for assessment
of heart rate control has been established to guide the manage-
ment of patients with AF. Criteria for rate control vary with
patient age but usually involve achieving ventricular rates
between 60 and 80 beats per minute at rest and between 90 and
115 beats per minute during moderate exercise.
Patients who are symptomatic with rapid ventricular rates
during AF require prompt medical management, and cardio-
version should be considered if symptomatic hypotension,
angina, or HF is present. A sustained, uncontrolled
tachycardia may lead to deterioration of ventricular function
(tachycardia-related cardiomyopathy) that improves with ad-
equate rate control. Tachycardia-induced cardiomyopathy
tends to resolve within 6 mo of rate or rhythm control; when
tachycardia recurs, LV ejection fraction declines and HF
develops over a shorter period, and this is associated with a
relatively poor prognosis (137).
a. Pharmacological Rate Control During Atrial Fibrillation
The functional refractory period of the AV node correlates
inversely with ventricular rate during AF, and drugs that
prolong the refractory period are generally effective for rate
control. There is no evidence that pharmacological rate
control has any adverse influence on LV function, but
bradycardia and heart block may occur as an unwanted effect
of beta blockers, amiodarone, digitalis glycosides, or nondi-
hydropyridine calcium channel antagonists, particularly in
patients with paroxysmal AF, especially the elderly. When
rapid control of the ventricular response to AF is required or
oral administration of medication is not feasible, medication
may be administered intravenously. Otherwise, in hemody-
namically stable patients with a rapid ventricular response to
AF, negative chronotropic medication may be administered
orally (Table 7). Combinations may be necessary to achieve
rate control in both acute and chronic situations. Some
patients develop symptomatic bradycardia that requires per-
manent pacing. Nonpharmacological therapy should be con-
sidered when pharmacological measures fail.
Special considerations in patients with the Wolff-Parkinson-
White syndrome.
Intravenous administration of beta blockers, digitalis, adeno-
sine, lidocaine, and nondihydropyridine calcium channel antag-
onists, all of which slow conduction across the AV node, is
contraindicated in patients with the WPW syndrome and
tachycardia associated with ventricular preexcitation because
they can facilitate antegrade conduction along the accessory
pathway during AF (2), resulting in acceleration of the ventric-
ular rate, hypotension, or ventricular fibrillation (62). When the
arrhythmia is associated with hemodynamic compromise, how-
ever, early direct-current cardioversion is indicated. In hemody-
namically stable patients with preexcitation, type I antiarrhyth-
mic agents or amiodarone may be administered intravenously.
Beta blockers and calcium channel blockers are reasonable for
oral maintenance therapy (138).
Pharmacological therapy to control heart rate in patients
with both atrial fibrillation and atrial flutter.
A patient treated with AV nodal blocking drugs whose
ventricular rate is well controlled during AF may experience a
rise or fall in rate if he or she develops atrial flutter. This is also
true when antiarrhythmic agents such as propafenone or flecain-
ide are used to prevent recurrent AF. These compounds may
increase the likelihood of 1:1 AV conduction during atrial flutter
leading to a very rapid ventricular response. Thus, when these
agents are given for prophylaxis against recurrent paroxysmal
AF or atrial flutter, AV nodal blocking drugs should be routinely
coadministered. An exception may be patients with paroxysmal
AF who have undergone catheter ablation of the cavotricuspid
isthmus to prevent atrial flutter.
b. Regulation of Atrioventricular Nodal Conduction by Pacing
Because ventricular pacing prolongs the AV nodal refractory
period as a result of concealed retrograde penetration, it
eliminates longer ventricular cycles and may reduce the
number of short ventricular cycles related to rapid AV
conduction during AF. Pacing at approximately the mean
ventricular rate during spontaneous AV conduction can reg-
ulate the ventricular rhythm during AF (139). This may be
useful for patients with marked variability in ventricular rates
or for those who develop resting bradycardia during treatment
with medication. In some patients, the hemodynamic benefit
of revascularization may be offset by asynchronous ventric-
ular activation during right ventricular pacing.
c. Atrioventricular Nodal Ablation
AV nodal ablation in conjunction with permanent pacemaker
implantation provides highly effective control of the heart
rate and improves symptoms in selected patients with AF
(140 –143). In general, patients most likely to benefit from
this strategy are those with symptoms or tachycardia-
mediated cardiomyopathy related to rapid ventricular rate
during AF that cannot be controlled adequately with antiar-
rhythmic or negative chronotropic medications. Meta-analy-
ses of 21 studies published between 1989 and 1998 that
included a total of 1181 patients concluded that AV nodal
ablation and permanent pacemaker implantation significantly
improved cardiac symptoms, quality of life, and healthcare
utilization for patients with symptomatic AF refractory to
medical treatment (143). Catheter ablation of inferior atrial
inputs to the AV node slows the ventricular rate during AF
and improves symptoms without pacemaker implantation
(144,145). This technique has several limitations, however,
including inadvertent complete AV block and a tendency of
ventricular rate to rise over the 6 mo following ablation.
Thus, AV nodal modification without pacemaker implanta-
tion is only rarely used.
Although the symptomatic benefits of AV nodal ablation are
clear, limitations include the persistent need for anticoagulation,
loss of AV synchrony, and lifelong pacemaker dependency.
There is also a finite risk of sudden death due to torsades de
pointes or ventricular fibrillation (146). Patients with abnormal-
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ities of diastolic ventricular compliance who depend on AV
synchrony to maintain cardiac output, such as those with HCM
or hypertensive heart disease, may experience persistent symp-
toms after AV nodal ablation and pacemaker implantation.
Hence, patients should be counseled regarding each of these
considerations before proceeding with this irreversible measure.
Patients with normal LV function or reversible LV dys-
function undergoing AV nodal ablation are most likely to
TABLE 7. Intravenous and Orally Administered Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation
Drug
Class/LOE
Recommendation Loading Dose Onset Maintenance Dose Major Side Effects
ACUTE SETTING
Heart rate control in patients without accessory
pathway
Esmolol*† Class I, LOE C 500 mcg/kg IV over 1 min 5 min 60 to 200 mcg/kg/min IV 2BP, HB,2HR, asthma, HF
Metoprolol† Class I, LOE C 2.5 to 5 mg IV bolus over 2
min; up to 3 doses
5 min NA 2BP, HB,2HR, asthma, HF
Propranolol† Class I, LOE C 0.15 mg/kg IV 5 min NA 2BP, HB,2HR, asthma, HF
Diltiazem Class I, LOE B 0.25 mg/kg IV over 2 min 2 to 7 min 5 to 15 mg/h IV 2BP, HB, HF
Verapamil Class I, LOE B 0.075 to 0.15 mg/kg IV over 2
min
3 to 5 min NA 2BP, HB, HF
Heart rate control in patients with accessory
pathway§
Amiodarone‡ Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min IV 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE B 0.25 mg IV each 2 h, up to
1.5 mg
60 min or more§ 0.125 to 0.375 mg daily IV or
orally
Digitalis toxicity, HB,2HR
Amiodarone‡ Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min IV 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
NON-ACUTE SETTING and CHRONIC MAINTENANCE THERAPY¶
Heart rate control
Metoprolol† Class I, LOE C Same as maintenance dose 4 to 6 h 25 to 100 mg twice a day,
orally
2BP, HB,2HR, asthma, HF
Propranolol† Class I, LOE C Same as maintenance dose 60 to 90 min 80 to 240 mg daily in divided
doses, orally
2BP, HB,2HR, asthma, HF
Diltiazem Class I, LOE B Same as maintenance dose 2 to 4 h 120 to 360 mg daily in
divided doses; slow release
available, orally
2BP, HB, HF
Verapamil Class I, LOE B Same as maintenance dose 1 to 2 h 120 to 360 mg daily in
divided doses; slow release
available, orally
2BP, HB, HF, digoxin interaction
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE C 0.5 mg by mouth daily 2 days 0.125 to 0.375 mg daily,
orally
Digitalis toxicity, HB,2HR
Amiodarone‡ Class IIb, LOE C 800 mg daily for 1 wk, orally
600 mg daily for 1 wk, orally
400 mg daily for 4 to 6 wk,
orally
1 to 3 wk 200 mg daily, orally 2BP, HB, pulmonary toxicity, skin
discoloration, hypothyroidism,
hyperthyroidism, corneal deposits,
optic neuropathy, warfarin
interaction, sinus bradycardia
*Onset is variable and some effect occurs earlier.
†Only representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this indication
in appropriate doses. Beta blockers are grouped in an order preceding the alphabetical listing of drugs.
‡Amiodarone can be useful to control the heart rate in patients with atrial fibrillation (AF) when other measures are unsuccessful or contraindicated.
§Conversion to sinus rhythm and catheter ablation of the accessory pathway are generally recommended; pharmacological therapy for rate control may be
appropriate in certain patients.
If rhythm cannot be converted or ablated and rate control is needed, intravenous (IV) amiodarone is recommended.
¶Adequacy of heart rate control should be assessed during physical activity as well as at rest.
2BP indicates hypotension; 2HR, bradycardia; HB, heart block; HF, heart failure; LOE, level of evidence; and NA, not applicable.
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benefit from standard AV nodal ablation and pacemaker
implantation. For those with impaired LV function not due to
tachycardia, a biventricular pacemaker with or without defi-
brillator capability should be considered. Upgrading to a
biventricular device should be considered for patients with
HF and a right ventricular pacing system who have under-
gone AV node ablation (147).
2. Preventing Thromboembolism
a. Risk Stratification
Epidemiological data.
In a small, retrospective, population-based study in Olmsted
County, Minnesota, over 3 decades, the 15-y cumulative stroke
rate in people with lone AF (defined as those younger than 60 y
with no clinical history or echocardiographic signs of cardiopul-
monary disease) was 1.3% (5). In the SPAF (Stroke Prevention
in Atrial Fibrillation III) studies, the annualized rate of ischemic
stroke during aspirin treatment was similar in those with parox-
ysmal (3.2%) and permanent (3.3%) AF (148). Those with prior
stroke or TIA have a rate of subsequent stroke of 10% to 12%
per year when treated with aspirin, and these patients benefit
substantially from adjusted-dose oral anticoagulation (149). In
addition to prior thromboembolism, HF, hypertension, increas-
ing age, and diabetes mellitus have consistently emerged as
independent risk factors for ischemic stroke associated with
nonvalvular AF (96). Other factors, such as female gender,
systolic blood pressure over 160 mm Hg, and LV dysfunction,
have been variably linked to stroke (96). The relative risk for
ischemic stroke associated with specific clinical features, de-
rived from a collaborative analysis of participants given no
antithrombotic therapy in the control groups of 5 randomized
trials, is displayed in Table 8. In patients with nonvalvular AF,
prior stroke or TIA is the strongest independent predictor of
stroke, significantly associated with stroke in all 6 studies in
which it was evaluated, with incremental relative risk between
1.9 and 3.7 (averaging approximately 3.0). All patients with
prior stroke or TIA require anticoagulation unless contraindica-
tions exist in a given patient. Patient age is a consistent
independent predictor of stroke (Fig. 3), but older people are also
at increased risk for anticoagulant-related bleeding (150). Spe-
cial consideration of these older patients is therefore a critical
aspect of effective stroke prophylaxis (151).
Echocardiography and risk stratification.
Echocardiography is valuable to define the origin of AF
(e.g., detecting rheumatic mitral valve disease or HCM) and
may add information useful in stratifying thromboembolic
risk. Among high-risk AF patients, impaired LV systolic
function on transthoracic echocardiography, thrombus, dense
spontaneous echo contrast or reduced velocity of blood flow
in the LAA, and complex atheromatous plaque in the thoracic
aorta on TEE have been associated with thromboembolism,
and oral anticoagulation effectively lowers the risk of stroke
in AF patients with these features. LA diameter and fibrocal-
cific endocardial abnormalities have been less consistently
associated with thromboembolism. Whether the absence of
these echocardiographic abnormalities identifies a low-risk
group of patients who could safely avoid anticoagulation has
not been established, limiting the value of echocardiography
as a prime determinant of the need for chronic anticoagula-
tion in patients with AF.
Several clinical schemes have been proposed to stratify the
risk of ischemic stroke in patients with AF, based on analyses
of prospectively monitored cohorts of participants in clinical
trials in which antithrombotic therapy was controlled. Other
criteria have been developed by expert consensus to classify
patients into low-, intermediate-, and high-risk groups. Still
others have used recursive partitioning and other techniques
to identify low-risk patients. The CHADS2 (Cardiac Failure,
Hypertension, Age, Diabetes, Stroke [Doubled]) integrates
elements from several of these schemes and is based on a
point system in which 2 points are assigned for a history of
stroke or TIA and 1 point each is assigned for age over 75 y
and a history of hypertension, diabetes, or recent HF (Table 9)
(152,153). The predictive value of this scoring system was
evaluated in 1733 Medicare beneficiaries with nonvalvular
AF between the ages of 65 and 95 y who were not given
warfarin at hospital discharge. Although high scores were
associated with an increased stroke rate in this elderly cohort,
few patients had a score of 5 or more or a score of 0.
Although these schemes for stratification of stroke risk
identify patients who benefit most and least from anticoagu-
lation, the threshold for use of anticoagulation is controver-
sial. Opinion is particularly divided about anticoagulation for
those at intermediate risk (stroke rate 3% to 5% per year).
Some advocate the routine use of anticoagulation in those
with stroke rates in this range (154), whereas others favor
selective anticoagulation of patients at intermediate risk, with
weight given to individual bleeding risks and patient prefer-
ences (24), The threshold of benefit at which AF patients
choose anticoagulation varies; some at intermediate risk elect
TABLE 8. Risk Factors for Ischemic Stroke and Systemic
Embolism in Patients With Nonvalvular Atrial Fibrillation
Risk Factors Relative Risk
Previous stroke or TIA 2.5
Diabetes mellitus 1.7
History of hypertension 1.6
Heart failure 1.4
Advanced age (continuous, per decade) 1.4
Data derived from collaborative analysis of 5 untreated control groups in
primary prevention trials (17). As a group, patients with nonvalvular atrial
fibrillation (AF) carry about a 6-fold increased risk of thromboembolism
compared with patients in sinus rhythm. Relative risk refers to comparison of
patients with AF to patients without these risk factors.
TIA indicates transient ischemic attack.
Figure 3. Stroke rates in relation to age among patients in
untreated control groups of randomized trials of antithrombotic
therapy. Data are from the Atrial Fibrillation Investigators. Risk
factors for stroke and efficacy of antithrombotic therapy in atrial
fibrillation. Analysis of pooled data from five randomized con-
trolled trials. Arch Intern Med 1994;154:1449 –1457 (17).
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anticoagulation, whereas others do not (155). Our recommen-
dations for antithrombotic therapy in patients with AF are
summarized in Table 10.
The risk of thromboembolism is not as well established for
atrial flutter as it is for AF but is generally estimated as higher
than that for patients with sinus rhythm and less than that for
those with persistent or permanent AF. Although the overall
thromboembolic risk associated with atrial flutter may be
somewhat lower than with AF (156), it seems prudent to
estimate risk by the use of similar stratification criteria for
both arrhythmias until more robust data become available.
b. Antithrombotic Strategies for Prevention of Ischemic
Stroke and Systemic Embolism
Before 1990, antithrombotic therapy for prevention of ische-
mic stroke and systemic embolism in patients with AF was
limited mainly to those with rheumatic heart disease or
prosthetic heart valves (23). Anticoagulation was also ac-
cepted therapy for patients who had sustained ischemic stroke
to prevent recurrence but was often delayed to avoid hemor-
rhagic transformation. Some advocated anticoagulation of
patients with thyrotoxicosis or other conditions associated
with cardiomyopathy. Since then, 24 randomized trials in-
volving patients with nonvalvular AF have been published,
including 20 012 participants with an average follow-up of
1.6 y, a total exposure of about 32 800 patient-y.
Anticoagulation with vitamin K antagonist agents.
Five large randomized trials published between 1989 and
1992 evaluated oral anticoagulation mainly for primary pre-
vention of thromboembolism in patients with nonvalvular AF
(157–163) (Fig. 4). A sixth trial focused on secondary
prevention among patients who had survived nondisabling
stroke or cerebral TIA (164). Meta-analysis according to the
principle of intention to treat showed that adjusted-dose oral
anticoagulation is highly efficacious for prevention of all
stroke (both ischemic and hemorrhagic), with a risk reduction
of 61% (95% CI 47% to 71%) versus placebo (165) (Fig. 4).
The duration of follow-up was generally between 1 and 2 y;
the longest was 2.2 y, whereas in clinical practice, the need
for antithrombotic therapy in patients with AF typically
extends over much longer periods.
All reported trials excluded patients considered at high risk
of bleeding. Patient age and the intensity of anticoagulation
are the most powerful predictors of major bleeding (166 –
169). Trial participants, at an average age of 69 y, were
carefully selected and managed, however, and it is unclear
whether the relatively low observed rates of major hemor-
rhage also apply to patients with AF in clinical practice, who
have a mean age of about 75 y and less closely regulated
anticoagulation therapy.
The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
TABLE 9. Stroke Risk in Patients With Nonvalvular AF Not
Treated With Anticoagulation According to the CHADS2 Index
CHADS2 Risk Criteria Score
Prior stroke or TIA 2
Age 75 y 1
Hypertension 1
Diabetes mellitus 1
Heart failure 1
Patients
(N1733)
Adjusted Stroke
Rate (%/y)*
(95% CI) CHADS2 Score
120 1.9 (1.2 to 3.0) 0
463 2.8 (2.0 to 3.8) 1
523 4.0 (3.1 to 5.1) 2
337 5.9 (4.6 to 7.3) 3
220 8.5 (6.3 to 11.1) 4
65 12.5 (8.2 to 17.5) 5
5 18.2 (10.5 to 27.4) 6
*The adjusted stroke rate was derived from multivariate analysis assuming
no aspirin usage. Data are from van Walraven WC, Hart RG, Wells GA, et al. A
clinical prediction rule to identify patients with atrial fibrillation and a low risk
for stroke while taking aspirin. Arch Intern Med 2003;163:936 – 43 (153); and
Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification
schemes for predicting stroke: results from the National Registry of Atrial
Fibrillation. JAMA 2001;285:2864 –70 (152).
AF indicates atrial fibrillation; CHADS2, Cardiac Failure, Hypertension, Age,
Diabetes, and Stroke (Doubled); CI, confidence interval; and TIA, transient
ischemic attack.
TABLE 10. Antithrombotic Therapy for Patients With Atrial Fibrillation
Risk Category Recommended Therapy
No risk factors Aspirin, 81 to 325 mg daily
One moderate-risk factor Aspirin, 81 to 325 mg daily, or warfarin (INR 2.0
to 3.0, target 2.5)
Any high-risk factor or more than 1
moderate-risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)*
Less Validated or Weaker
Risk Factors Moderate-Risk Factors High-Risk Factors
Female gender Age greater than or equal to 75 y Previous stroke, TIA or embolism
Age 65 to 74 y Hypertension Mitral stenosis
Coronary artery disease Heart failure Prosthetic heart valve*
Thyrotoxicosis LV ejection fraction 35% or less
Diabetes mellitus
*If mechanical valve, target international normalized ratio (INR) greater than 2.5.
INR indicates international normalized ratio; LV, left ventricular; and TIA, transient ischemic attack.
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hemorrhagic complications (Fig. 5). Targeting the lowest
adequate intensity of anticoagulation to minimize the risk of
bleeding is particularly important for elderly AF patients.
Maximum protection against ischemic stroke in AF is prob-
ably achieved at an INR range of 2.0 to 3.0 (170). Despite
anticoagulation of more elderly patients with AF, rates of
intracerebral hemorrhage are considerably lower than in the
past, typically between 0.1% and 0.6% in contemporary
reports. This may reflect lower anticoagulation intensity,
more careful dose regulation, or better control of hyperten-
sion (171–173).
Aspirin for antithrombotic therapy in patients with atrial
fibrillation.
Aspirin offers only modest protection against stroke for
patients with AF (157,161,164,174 –180) (Fig. 6). Meta-anal-
ysis of 5 randomized trials showed a stroke reduction of 19%
(95% CI2% to 34%) (165). Aspirin may be more effica-
cious for AF patients with hypertension or diabetes (181) and
for reduction of noncardioembolic versus cardioembolic is-
chemic strokes in AF patients (72). Cardioembolic strokes
are, on average, more disabling than noncardioembolic
strokes (92). Aspirin appears to prevent nondisabling strokes
more than disabling strokes (165). Thus, the greater the risk
of disabling cardioembolic stroke in a population of patients
with AF, the less protection is afforded by aspirin (92).
Combining anticoagulant and platelet-inhibitor therapy.
Combinations of oral anticoagulants plus antiplatelet agents
have not generally shown reduced risks of hemorrhage or
augmented efficacy over adjusted-dose anticoagulation alone.
Combining aspirin with an oral anticoagulant at higher
intensities may accentuate intracranial hemorrhage, particu-
larly in elderly AF patients (183). For most patients with AF
who have stable CAD, warfarin anticoagulation alone (target
INR 2.0 to 3.0) should provide satisfactory antithrombotic
prophylaxis against both cerebral and myocardial ischemic
events.
Platelet-inhibitor drugs are particularly valuable for pre-
vention of recurrent myocardial ischemia in patients under-
going percutaneous coronary intervention, but no adequate
studies have been published that specifically address this
issue in patients who also require chronic anticoagulation
because of AF. It is the consensus of the authors of these
guidelines that the most important agent for the maintenance
of coronary and stent patency is the thienopyridine derivative
clopidogrel and that the addition of aspirin to the chronic
anticoagulant regimen contributes more risk than benefit.
Although it is usually necessary to interrupt or reduce
anticoagulation to prevent bleeding at the site of peripheral
arterial puncture, the vitamin K antagonist should be resumed
as soon as possible after the procedure and the dose adjusted
to achieve an INR in the therapeutic range. Aspirin may be
given temporarily during the hiatus, but the maintenance
regimen should then consist of the combination of clopi-
dogrel, 75 mg daily, plus warfarin (INR 2.0 to 3.0) for 9 to 12
mo, after which warfarin may be continued as monotherapy
in the absence of a subsequent coronary event.
Low-molecular-weight heparins.
The use of low-molecular-weight heparin instead of un-
fractionated heparin in patients with AF is based largely on
extrapolation from venous thromboembolic disease states and
from limited observational studies (184). In general, low-
molecular-weight heparins have several pharmacological ad-
vantages over unfractionated heparin. These include a longer
half-life, more predictable bioavailability (greater than 90%
Figure 4. Antithrombotic therapy for prevention of stroke (ische-
mic and hemorrhagic) in patients with nonvalvular atrial fibrilla-
tion. Adjusted-dose warfarin compared with placebo (six ran-
dom trials). Modified with permission from Hart RG, Benavente
O, McBride R, et al. Antithrombotic therapy to prevent stroke in
patients with atrial fibrillation: a meta-analysis. Ann Intern Med
1999;131:492–501 (165). AFASAK indicates Copenhagen Atrial
Fibrillation, Aspirin, Anticoagulation; BAATAF, Boston Area Anti-
coagulation Trial for Atrial Fibrillation; CAFA, Canadian Atrial
Fibrillation Anticoagulation; EAFT, European Atrial Fibrillation
Trial; SPAF, Stroke Prevention in Atrial Fibrillation; and SPINAF,
Stroke Prevention in Nonrheumatic Atrial Fibrillation.
Figure 5. Adjusted odds ratios for ischemic stroke and intracra-
nial bleeding in relation to intensity of anticoagulation. Modified
with permission from Hylek EM, Singer DE. Risk factors for
intracranial hemorrhage in outpatients taking warfarin. Ann
Intern Med 1994;120:897–902 (166). Data from Odén A, Fahlén
M, Hart RG. Optimal INR for prevention of stroke and death in
atrial fibrillation: a critical appraisal. Thromb Res 2006;117:493–9
(167).
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after subcutaneous injection), predictable clearance (enabling
once- or twice-daily subcutaneous administration), and a
predictable antithrombotic response based on body weight,
which permits fixed-dose treatment without laboratory mon-
itoring except under special circumstances such as obesity,
renal insufficiency, or pregnancy (185). The favorable prop-
erties of low-molecular-weight heparins may simplify the
treatment of AF in acute situations and shorten or eliminate
the need for hospitalization to initiate anticoagulation. Self-
administration of low-molecular-weight heparins out of hos-
pital by patients with AF undergoing elective cardioversion is
a promising approach that may result in cost savings (186).
Interruption of anticoagulation for diagnostic or therapeutic
procedures.
From time to time, it may be necessary to interrupt oral
anticoagulant therapy in preparation for elective surgical proce-
dures. In patients with mechanical prosthetic heart valves, it is
generally appropriate to substitute unfractionated or low-
molecular-weight heparin to prevent thrombosis (187). In pa-
tients with AF who do not have mechanical valves, however,
based on extrapolation from the annual rate of thromboembo-
lism in patients with nonvalvular AF, it is the consensus of the
Writing Group that anticoagulation may be interrupted for a
period of up to 1 wk for surgical or diagnostic procedures that
carry a risk of bleeding without substituting heparin. In high-risk
patients (particularly those with prior stroke, TIA, or systemic
embolism), or when a series of procedures requires interruption
of oral anticoagulant therapy for longer periods, unfractionated
or low-molecular-weight heparin may be administered intrave-
nously or subcutaneously.
c. Nonpharmacological Approaches to Prevention of
Thromboembolism
An emerging option for patients with AF who cannot safely
undergo anticoagulation, not yet sufficiently investigated to
TABLE 11. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation of Up to 7-d Duration
Drug* Route of Administration
Class of
Recommendation
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 197–202
Flecainide Oral or intravenous I A 191, 203–210
Ibutilide Intravenous I A 211–216
Propafenone Oral or intravenous I A 191, 193, 195, 207, 210, 217–227, 255
Amiodarone Oral or intravenous IIa A 194, 206, 217, 228–235
Less effective or incompletely studied agents
Disopyramide Intravenous IIb B 247
Procainamide Intravenous IIb B 211, 213, 239
Quinidine Oral IIb B 195, 203, 225, 230, 236–238, 273
Should not be administered
Digoxin Oral or intravenous III A 195, 207, 227, 231, 241, 245
Sotalol Oral or intravenous III A 214, 237, 238, 242, 246
*The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within each
category of recommendation and level of evidence.
TABLE 12. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation Present for More Than 7 d
Drug* Route of Administration
Recommendation
Class
Level of
Evidence References
Agents with proven efficacy
Dofetilide Oral I A 197–202
Amiodarone Oral or intravenous IIa A 194, 206, 217, 228–235
Ibutilide Intravenous IIa A 211–216
Less effective or incompletely studied agents
Disopyramide Intravenous IIb B 247
Flecainide Oral IIb B 191, 203–210
Procainamide Intravenous IIb C 211, 213, 239
Propafenone Oral or intravenous IIb B 191, 193, 195, 207, 210, 217–227, 248, 255
Quinidine Oral IIb B 195, 203, 225, 230, 236–238, 273
Should not be administered
Digoxin Oral or intravenous III B 195, 207, 227, 231, 241–243, 245
Sotalol Oral or intravenous III B 214, 237, 238, 242, 246
*The doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within each
category by class and level of evidence.
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allow general clinical application, is obliteration of the LAA
to remove a principal nidus of thrombus formation (188). In
addition to direct surgical amputation or truncation of ap-
pendage, several methods are under development to achieve
this with intravascular catheters or transpericardial ap-
proaches (189). The efficacy of these techniques is presum-
ably related to the completeness and permanence of elimina-
tion of blood flow into and out of the LAA. This has been
demonstrated by TEE at the time of intervention, but the
durability of the effect has not been confirmed by subsequent
examinations over several years. Whether mechanical mea-
sures intended to prevent embolism from thrombotic material
in the LAA will prove comparably effective and safer than
anticoagulation for some patients remains to be established
(190).
3. Cardioversion of Atrial Fibrillation
Cardioversion may be performed electively to restore sinus
rhythm in patients with persistent AF. The need for cardio-
version may be immediate when the arrhythmia is the main
factor responsible for acute HF, hypotension, or worsening of
angina pectoris in a patient with CAD. Nevertheless, cardio-
version carries a risk of thromboembolism unless anticoagu-
lation prophylaxis is initiated before the procedure, and this
risk is greatest when the arrhythmia has been present more
than 48 h.
Cardioversion may be achieved by means of drugs or
electrical shocks. Drugs were commonly used before direct-
current cardioversion became a standard procedure. The
development of new drugs has increased the popularity of
pharmacological cardioversion, but the disadvantages include
the risk of drug-induced torsades de pointes or other serious
arrhythmias. Moreover, pharmacological cardioversion is less
effective than direct-current cardioversion when biphasic
shocks are used. The disadvantage of electrical cardioversion
is that it requires conscious sedation or anesthesia, which
pharmacological cardioversion does not.
There is no evidence that the risk of thromboembolism or
stroke differs between pharmacological and electrical meth-
ods of cardioversion. The recommendations for anticoagula-
TABLE 13. Recommended Doses of Drugs Proven Effective for Pharmacological Cardioversion of Atrial Fibrillation
Drug* Route of Administration Dosage† Potential Adverse Effects References
Amiodarone Oral Inpatient: 1.2 to 1.8 g per day in
divided dose until 10 g total, then
200 to 400 mg per day
maintenance or 30 mg/kg as single
dose
Outpatient: 600 to 800 mg per day
divided dose until 10 g total, then
200 to 400 mg per day
maintenance
Hypotension, bradycardia, QT prolongation,
torsades de pointes (rare), GI upset,
constipation, phlebitis (IV)
194, 206, 217, 228–236, 250
Intravenous/oral 5 to 7 mg/kg over 30 to 60 min,
then 1.2 to 1.8 g per day continuous
IV or in divided oral doses until 10 g
total, then 200 to 400 mg per day
maintenance
Dofetilide Oral Creatinine
Clearance Dose
(mL/min) (mcg BID)
More than 60
40 to 60
20 to 40
Less than 20
500
250
125
Contraindicated
QT prolongation, torsades de pointes; adjust
dose for renal function, body size and age
197–202
Flecainide Oral 200 to 300 mg‡ Hypotension, atrial flutter with high ventricular
rate
191, 203–210
Intravenous 1.5 to 3.0 mg/kg over 10 to 20
min‡
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg
when necessary
QT prolongation, torsades de pointes 211–216
Propafenone Oral 600 mg Hypotension, atrial flutter with high ventricular
rate
191, 193, 195, 207, 210, 217–227,
248, 255Intravenous 1.5 to 2.0 mg/kg over 10 to 20
min‡
Quinidine§ Oral 0.75 to 1.5 g in divided doses over
6 to 12 h, usually with a
rate-slowing drug
QT prolongation, torsades de pointes, GI upset,
hypotension
195, 203, 225, 230, 236–238
*Drugs are listed alphabetically.
†Dosages given in the table may differ from those recommended by the manufacturers.
‡Insufficient data are available on which to base specific recommendations for the use of one loading regimen over another for patients with ischemic heart disease
or impaired left ventricular function, and these drugs should be used cautiously or not at all in such patients.
§The use of quinidine loading to achieve pharmacological conversion of atrial fibrillation is controversial and safer methods are available with the alternative agents
listed in the table. Quinidine should be used with caution.
AF indicates atrial fibrillation; BID, twice a day; GI, gastrointestinal; and IV, intravenous.
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tion are therefore the same for both methods, as outlined in
Section I.C.2, Preventing Thromboembolism. Cardioversion
in patients with AF following recent heart surgery or MI is
addressed later (see Section I.C.5, Special Considerations).
a. Pharmacological Cardioversion
The quality of evidence available to gauge the effectiveness
of pharmacological cardioversion is limited by small samples,
lack of standard inclusion criteria (many studies include both
patients with AF and those with atrial flutter), variable
intervals from drug administration to assessment of outcome,
and arbitrary dose selection. Although pharmacological and
direct-current cardioversion have not been compared directly,
pharmacological approaches appear simpler but are less
efficacious. The major risk is related to the toxicity of
antiarrhythmic drugs. In developing these guidelines,
placebo-controlled trials of pharmacological cardioversion in
which drugs were administered over short periods of time
specifically to restore sinus rhythm have been emphasized.
Trials in which the control group was given another antiar-
rhythmic drug have, however, been considered as well.
Pharmacological cardioversion seems most effective when
initiated within 7 d after the onset of an episode of AF
(191,192). A majority of these patients have a first-
documented episode of AF or an unknown pattern of AF at
the time of treatment. (See Section III, Classification.) A
large proportion of patients with recent-onset AF experience
spontaneous cardioversion within 24 to 48 h (193). Sponta-
neous conversion is less frequent in patients with AF of
longer than 7-d duration, and the efficacy of pharmacological
cardioversion is markedly reduced in these patients as well.
Pharmacological cardioversion may accelerate restoration of
sinus rhythm in patients with recent-onset AF, but the
advantage over placebo is modest after 24 to 48 h, and drug
therapy is much less effective in patients with persistent AF.
Some drugs have a delayed onset of action, and conversion
may not occur for several days after initiation of treatment
(194). Drug treatment abbreviated the interval to cardiover-
sion compared with placebo in some studies without affecting
the proportion of patients who remained in sinus rhythm after
24 h (195). A potential interaction of antiarrhythmic drugs
with vitamin K antagonist oral anticoagulants, increasing or
decreasing the anticoagulant effect, is an issue whenever
these drugs are added or withdrawn from the treatment
regimen. The problem is amplified when anticoagulation is
initiated in preparation for elective cardioversion. Addition of
an antiarrhythmic drug to enhance the likelihood that sinus
rhythm will be restored and maintained may perturb the
intensity of anticoagulation beyond the intended therapeutic
range, raising the risk of bleeding or thromboembolic
complications.
A summary of recommendations concerning the use of
pharmacological agents and recommended doses for cardiover-
sion of AF is presented in Tables 11, 12, and 13. Algorithms for
pharmacological management of AF are given in Figures 7, 8, 9,
and 10. Throughout this document, reference is made to the
Vaughan Williams classification of antiarrhythmic drugs (196),
modified to include drugs that became available after the
original classification was developed (Table 14). The recom-
mendations given in this document are based on published data
and do not necessarily adhere to the regulations and labeling
requirements of governmental agencies. These antiarrhythmic
drugs have been approved by federal regulatory agencies in the
United States and/or Europe for clinical use, but their use for the
treatment of AF has not been approved in all cases. Furthermore,
not all agents are approved for use in all countries.
4. Pharmacological Agents to Maintain Sinus Rhythm
a. Agents With Proven Efficacy to Maintain Sinus Rhythm
Thirty-six controlled trials evaluating 7 antiarrhythmic drugs
for the maintenance of sinus rhythm in patients with parox-
Figure 6. Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular atrial fibrillation: war-
farin compared with aspirin and aspirin compared with placebo. Modified with permission from Hart RG, Benavente O, McBride R,
Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–
501 (165). AFASAK indicates Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation; EAFT, European Atrial Fibrillation Trial; ESPS,
European Stroke Prevention Study; LASAF, Low-Dose Aspirin, Stroke, Atrial Fibrillation; UK-TIA, United Kingdom Transient Ischaemic
Attack Aspirin Trial; PATAF, Prevention of Arterial Thromboembolism in Atrial Fibrillation; SPAF, Stroke Prevention in Atrial Fibrillation;
and SPINAF, Stroke Prevention in Nonrheumatic Atrial Fibrillation.
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ysmal or persistent AF, 14 controlled trials of drug prophy-
laxis involving patients with paroxysmal AF, and 22 trials of
drug prophylaxis for maintenance of sinus rhythm in patients
with persistent AF were identified. Comparative data are not
sufficient to permit subclassification by drug or etiology.
Individual drugs and doses for maintenance of sinus rhythm
are given in Table 15. It should be noted that any membrane
active agent may cause proarrhythmia.
b. Out-of-Hospital Initiation of Antiarrhythmic Drugs in
Patients With Atrial Fibrillation
A frequent issue related to pharmacological cardioversion of
AF is whether to initiate antiarrhythmic drug therapy in
hospital or on an outpatient basis. The major concern is the
potential for serious adverse effects, including torsades de
pointes. With the exception of those involving low-dose oral
amiodarone (234), virtually all studies of pharmacological
cardioversion have involved hospitalized patients. However,
1 study (251) provided a clinically useful approach with
out-of-hospital patient-controlled conversion using class IC
drugs.
The “pill-in-the-pocket” strategy consists of the self-
administration of a single oral dose of drug shortly after the
onset of symptomatic AF to improve quality of life, decrease
hospital admission, and reduce cost (252). Recommendations
for out-of-hospital initiation or intermittent use of antiar-
rhythmic drugs differ for patients with paroxysmal and
persistent AF. In patients with paroxysmal AF, the aims are to
terminate an episode or to prevent recurrence. In patients with
persistent AF, the aims are to achieve pharmacological
cardioversion of AF, obviating the need for direct-current
cardioversion, or to enhance the success of direct-current
cardioversion by lowering the defibrillation threshold and
prevent early recurrence of AF.
In patients with lone AF without structural heart disease,
class IC drugs may be initiated on an outpatient basis. For
other selected patients without sinus or AV node dysfunction,
bundle-branch block, QT-interval prolongation, the Brugada
syndrome, or structural heart disease, “pill-in-the-pocket”
administration of propafenone and flecainide outside the
hospital becomes an option once treatment has proved safe in
hospital, given the relative safety (lack of organ toxicity and
low estimated incidence of proarrhythmia) (253–255). Before
these agents are initiated, however, a beta blocker or nondi-
hydropyridine calcium channel antagonist is generally rec-
ommended to prevent rapid AV conduction in the event of
atrial flutter (256,257). Unless AV node conduction is im-
paired, a short-acting beta blocker or nondihydropyridine
TABLE 14. Vaughan Williams Classification of
Antiarrhythmic Drugs
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Propafenone
Type II
Beta blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Nondihydropyridine calcium channel antagonists (verapamil and diltiazem)
Table includes compounds introduced after publication of the original
classification.
Modified with permission from Vaughan Williams EM. A classification of
antiarrhythmic actions reassessed after a decade of new drugs. J Clin
Pharmacol 1984;24:129-47 (196). © 1984 by Sage Publications Inc.
Figure 7. Pharmacological management of
patients with newly discovered atrial fibrillation
(AF). *See Figure 9. HF indicates heart failure.
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calcium channel antagonist should be given at least 30 min
before administration of a type IC antiarrhythmic agent to
terminate an acute episode of AF, or the AV nodal blocking
agents should be prescribed as continuous background ther-
apy. Because termination of paroxysmal AF may be associ-
ated with bradycardia due to sinus node or AV node dysfunc-
tion, an initial conversion trial should be undertaken in
hospital before a patient is declared fit for outpatient “pill-
in-the pocket” use of flecainide or propafenone for conver-
sion of subsequent recurrences of AF. Table 16 lists other
factors associated with proarrhythmic toxicity to class IC
agents. It should be noted that these include female gender.
Few prospective data are available on the relative safety of
initiating antiarrhythmic drug therapy in the outpatient versus
inpatient setting, and the decision to initiate therapy out of
hospital should be carefully individualized. The “pill-in-the
pocket” approach appears feasible and safe for selected
patients with AF, but the safety of this approach without
previous inpatient evaluation remains uncertain.
As long as the baseline uncorrected QT interval is less than
460 ms, serum electrolytes are normal, and risk factors associ-
ated with class III drug–related proarrhythmia are considered
(Table 16), sotalol may be initiated in outpatients with little or no
heart disease. It is safest to start sotalol when the patient is in
Figure 8. Pharmacological management of
patients with recurrent paroxysmal atrial fibrillation
(AF). *See Figure 9. AAD indicates antiarrhythmic
drug.
Figure 9. Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation.
Within each box, drugs are listed alphabetically and not in order of suggested use. The vertical flow indicates order of preference under
each condition. The seriousness of heart disease proceeds from left to right, and selection of therapy in patients with multiple condi-
tions depends on the most serious condition present. See Section 8.3.3.3 in the full-text guidelines for details. LVH indicates left ven-
tricular hypertrophy.
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sinus rhythm. Amiodarone can also usually be given safely on an
outpatient basis, even in patients with persistent AF, because it
causes minimal depression of myocardial function and has low
proarrhythmic potential (258), but in-hospital loading may be
necessary for earlier restoration of sinus rhythm in patients with
HF or other forms of hemodynamic compromise related to AF.
Loading regimens typically call for administration of 600 mg
daily for 4 wk (258) or 1 g daily for 1 wk (232), followed by
lower maintenance doses. Amiodarone, class IA or IC agents, or
sotalol can be associated with bradycardia requiring permanent
pacemaker implantation (259); this is more frequent with ami-
odarone, and amiodarone-associated bradycardia is more com-
mon in women than in men. Quinidine, procainamide, and
disopyramide should not be started out of hospital and out-of-
hospital initiation of dofetilide is not currently permitted.
Transtelephonic monitoring or other methods of ECG sur-
veillance may be used to monitor cardiac rhythm and con-
duction as pharmacological antiarrhythmic therapy is initi-
ated in patients with AF. Specifically, the PR interval (when
flecainide, propafenone, sotalol, or amiodarone are used),
QRS duration (with flecainide or propafenone), and QT
interval (with dofetilide, sotalol, amiodarone, or disopyr-
amide) should be measured.
As a general rule, antiarrhythmic drugs should be started
at a relatively low dose and titrated based on response, and
the ECG should be reassessed after each dose change. The
heart rate should be monitored at approximately weekly
intervals, either by checking the pulse rate, by use of an
event recorder, or by ECG tracings obtained in the office.
The dose of other medication for rate control should be
reduced when the rate slows after initiation of amiodarone
and stopped if the rate slows excessively. Concomitant
drug therapies should be monitored closely, and both the
patient and the physician should be alert to possible
deleterious interactions. The doses of digoxin and warfa-
rin, in particular, should usually be reduced upon initiation
of amiodarone in anticipation of the rises in serum digoxin
levels and INR that typically occur.
Figure 10. Pharmacological management of
patients with recurrent persistent or perma-
nent atrial fibrillation (AF). *See Figure 9. Ini-
tiate drug therapy before cardioversion to
reduce the likelihood of early recurrence of
AF. AAD indicates antiarrhythmic drug.
TABLE 15. Typical Doses of Drugs Used to Maintain Sinus Rhythm in Patients With Atrial Fibrillation*
Drug† Daily Dosage Potential Adverse Effects
Amiodarone‡ 100 to 400 mg Photosensitivity, pulmonary toxicity, polyneuropathy, GI upset, bradycardia, torsades de pointes
(rare), hepatic toxicity, thyroid dysfunction, eye complications
Disopyramide 400 to 750 mg Torsades de pointes, HF, glaucoma, urinary retention, dry mouth
Dofetilide§ 500 to 1000 mcg Torsades de pointes
Flecainide 200 to 300 mg Ventricular tachycardia, HF, conversion to atrial flutter with rapid conduction through the AV node
Propafenone 450 to 900 mg Ventricular tachycardia, HF, conversion to atrial flutter with rapid conduction through the AV node
Sotalol§ 160 to 320 mg Torsades de pointes, HF, bradycardia, exacerbation of chronic obstructive or bronchospastic lung
disease
*Drugs and doses given here have been determined by consensus on the basis of published studies.
†Drugs are listed alphabetically.
‡A loading dose of 600 mg per day is usually given for one month or 1000 mg per day for 1 week.
§Dose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
AF indicates atrial fibrillation; AV, atrioventricular; GI, gastrointestinal; and HF, heart failure.
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5. Direct-Current Cardioversion of Atrial Fibrillation and
Atrial Flutter
a. Technical and Procedural Aspects
Direct-current cardioversion involves delivery of an electrical
shock synchronized with the intrinsic activity of the heart by
sensing the R wave of the ECG to ensure that electrical
stimulation does not occur during the vulnerable phase of the
cardiac cycle (136), Direct-current cardioversion is used to
normalize all abnormal cardiac rhythms except ventricular
fibrillation. The term “defibrillation” implies an asynchro-
nous discharge, which is appropriate for correction of ven-
tricular fibrillation because R-wave synchronization is not
feasible, but not for AF.
Successful cardioversion of AF depends on the underlying
heart disease and the current density delivered to the atrial
myocardium. Current may be delivered through external
chest wall electrodes or through an internal cardiac electrode.
Although the latter technique has been considered superior to
external countershocks in obese patients and in patients with
obstructive lung disease, it has not been widely applied. The
frequency of recurrent AF does not differ between the 2
methods (135,260).
Cardioversion should be performed with the patient under
adequate general anesthesia in a fasting state. Short-acting
anesthetic drugs or agents that produce conscious sedation are
preferred to enable rapid recovery after the procedure; over-
night hospitalization is seldom required (261). The electric
TABLE 17. Types of Proarrhythmia During Treatment With
Various Antiarrhythmic Drugs for AF or Atrial Flutter According
to the Vaughan Williams Classification
A. Ventricular proarrhythmia
Torsades de pointes (VW types IA and III drugs*)
Sustained monomorphic ventricular tachycardia (usually VW type IC drugs)
Sustained polymorphic ventricular tachycardia/VF without long QT (VW
types IA, IC, and III drugs)
B. Atrial proarrhythmia
Provocation of recurrence (probably VW types IA, IC, and III drugs)
Conversion of AF to flutter (usually VW type IC drugs)
Increase of defibrillation threshold (a potential problem with VW type IC
drugs)
C. Abnormalities of conduction or impulse formation
Acceleration of ventricular rate during AF (VW types IA and IC drugs)
Accelerated conduction over accessory pathway (digoxin, intravenous
verapamil, or diltiazem†)
Sinus node dysfunction, atrioventricular block (almost all drugs)
Vaughan Williams (VW) classification of antiarrhythmic drugs from Vaughan
Williams EM. A classification of antiarrhythmic actions reassessed after a
decade of new drugs. J Clin Pharmacol 1984;24:129–47 (196).
*This complication is rare with amiodarone.
†Although the potential for beta blockers to potentiate conduction across the
accessory pathway is controversial, caution should also be exercised for the
use of these agents in patients with atrial fibrillation (AF) associated with
preexcitation.
VF indicates ventricular fibrillation.
TABLE 16. Factors Predisposing to Drug-Induced Ventricular Proarrhythmia
VW Types IA and III Agents VW Type IC Agents
Long QT interval (QTc greater than or equal to 460 ms) Wide QRS duration (more than 120 ms)
Long QT interval syndrome Concomitant VT
Structural heart disease, substantial LVH Structural heart disease
Depressed LV function* Depressed LV function*
Hypokalemia/hypomagnesemia*
Female gender
Renal dysfunction*
Bradycardia* Rapid ventricular response rate*
1. (Drug-induced) sinus node disease or AV block 1. During exercise
2. (Drug-induced) conversion of AF to sinus rhythm 2. During rapid AV conduction
3. Ectopy producing short-long R-R sequences
Rapid dose increase Rapid dose increase
High dose (sotalol, dofetilide), drug accumulation* High dose, drug accumulation*
Addition of drugs* Addition of drugs*
1. Diuretics 1. Negative inotropic drugs
2. Other QT-prolonging antiarrhythmic drugs
3. Nonantiarrhythmic drugs listed in http://www.torsades.org/
Previous proarrhythmia
After initiation of drug
Excessive QT lengthening Excessive (more than 150%) QRS widening
*Some of these factors may develop later after initiation of drug treatment. See Section 8.3.3.3 in the full-text
guidelines for details. Vaughan Williams (VW) classification of antiarrhythmic drugs from Vaughan Williams EM. A
classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129–47
(196).
AF indicates atrial fibrillation; AV, atrioventricular; LV, left ventricular; LVH, left ventricular hypertrophy; QTc,
indicates corrected QT interval; and VT, ventricular tachycardia.
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shock should be synchronized with the QRS complex,
triggered by monitoring the R wave with an appropriately
selected ECG lead that also clearly displays atrial activa-
tion to facilitate assessment of outcome. In 64 patients
randomly assigned to initial monophasic waveform ener-
gies of 100, 200, or 360 J, high initial energy was
significantly more effective than low levels (immediate
success rates 14% with 100, 39% with 200, and 95% with
360 J, respectively), resulting in fewer shocks and less
cumulative energy when 360 J was delivered initially
(262). These data indicate that an initial shock of 100 J
with monophasic waveform is often too low for direct-
current cardioversion of AF; hence, an initial energy of
200 J or greater is recommended. A similar recommenda-
tion to start with 200 J applies to biphasic waveforms,
particularly when cardioverting patients with AF of long
duration (263).
When appropriate precautions are taken, cardioversion of
AF is safe in patients with implanted pacemaker or defibril-
lator devices. Pacemaker generators and defibrillators are
designed with circuits protected against sudden external
electrical discharges, but programmed data may be altered by
current surges. Electricity conducted along an implanted
electrode may cause endocardial injury and lead to a tempo-
rary or permanent increase in stimulation threshold resulting
in loss of ventricular capture. To ensure appropriate function,
the implanted device should be interrogated and, if necessary,
reprogrammed before and after cardioversion.
b. Risks and Complications of Direct-Current
Cardioversion of Atrial Fibrillation
The risks of direct-current cardioversion are mainly related to
thromboembolism and arrhythmias. Thromboembolic events
have been reported in 1% to 7% of patients not given
prophylactic anticoagulation before cardioversion of AF
(264,265). Prophylactic antithrombotic therapy is discussed
in Section VIII.B.5.c, Pharmacological Enhancement of
Direct-Current Cardioversion.
c. Pharmacological Enhancement of Direct-Current
Cardioversion
Although most recurrences of AF occur within the first month
after direct-current cardioversion, research with internal atrial
cardioversion (270) and postconversion studies using trans-
thoracic shocks (271) have established several patterns of AF
recurrence (Fig. 7). In some cases, direct-current counter-
shock fails to elicit even a single isolated sinus or ectopic
atrial beat, tantamount to a high atrial defibrillation threshold.
In others, AF recurs within a few minutes after a period of
sinus rhythm (272), and recurrence after cardioversion is
sometimes delayed for days or weeks (271). Complete shock
failure and immediate recurrence occur in approximately
25% of patients undergoing direct-current cardioversion of
AF, and subacute recurrences occur within 2 wk in almost an
equal proportion (273).
Restoration and maintenance of sinus rhythm are less
likely when AF has been present for more than 1 y than in
patients with AF of shorter duration. The variation in imme-
diate success rates for direct-current cardioversion from 70%
to 99% in the literature (262,274 –276) is partly explained by
differences in patient characteristics and the waveform used
but also depends on the definition of success, because the
interval at which the result is evaluated ranges from moments
to several days. In general, it appears that sinus rhythm can be
restored in a substantial proportion of patients by direct-
current cardioversion, but the rate of relapse is high without
concomitant antiarrhythmic drug therapy.
TABLE 18. Pharmacological Treatment Before Cardioversion in Patients With Persistent AF:
Effectiveness of Various Antiarrhythmic Drugs on Acute and Subacute Outcome of
Transthoracic DC Shock
Efficacy
Enhance Conversion
by DC Shock and
Prevent IRAF*
Suppress SRAF and
Maintenance Therapy Class
Recommendation
Class
Level of
Evidence
Known Amiodarone All drugs in recommendation class I
(except ibutilide) plus beta blockers
I B
Flecainide
Ibutilide
Propafenone
Quinidine
Sotalol
Uncertain/unknown Beta-blockers Diltiazem IIb C
Diltiazem Dofetilide
Disopyramide Verapamil
Dofetilide
Procainamide
Verapamil
All drugs (except beta blockers and amiodarone) should be initiated in the hospital.
*Drugs are listed alphabetically within each class of recommendation.
AF indicates atrial fibrillation; DC, direct-current; IRAF, immediate recurrence of atrial fibrillation; and SRAF,
subacute recurrence of atrial fibrillation.
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When given in conjunction with direct-current cardioversion,
the primary aims of antiarrhythmic medication therapy are to
increase the likelihood of success (e.g., by lowering the cardio-
version threshold) and to prevent recurrent AF. Antiarrhythmic
medications may be initiated out of hospital or in hospital
immediately prior to direct-current cardioversion. (see Section
8.1.7 in the full-text guidelines, Out-of-Hospital Initiation of
Antiarrhythmic Drugs in Patients). The risks of pharmacological
treatment include the possibility of paradoxically increasing the
defibrillation threshold, as described with flecainide (277),
accelerating the ventricular rate when class IA or IC drugs are
given without an AV nodal blocking agent (256,257,278,279),
and inducing ventricular arrhythmias (Table 17).
Patients with lone AF of relatively short duration are less
prone to early recurrence of AF than are those with heart
disease and longer AF duration, who therefore stand to gain
more from prophylactic administration of antiarrhythmic
medication. Pretreatment with pharmacological agents is
most appropriate in patients who fail to respond to direct-
current cardioversion and in those who develop immediate or
subacute recurrence of AF. In patients with late recurrence
and those undergoing initial cardioversion of persistent AF,
pretreatment is optional. Antiarrhythmic drug therapy is
recommended in conjunction with a second cardioversion
attempt, particularly when early relapse has occurred. Addi-
tional cardioversion, beyond a second attempt, is of limited
value and should be reserved for carefully selected patients,
but infrequently repeated cardioversions may be acceptable in
patients who are highly symptomatic upon relapse to AF.
Available data suggest that starting pharmacological therapy
and establishing therapeutic plasma drug concentrations before
direct-current cardioversion enhances immediate success and
suppresses early recurrences. After cardioversion to sinus
rhythm, patients receiving drugs that prolong the QT interval
should be monitored in the hospital for 24 to 48 h to evaluate the
effects of heart rate slowing and allow for prompt intervention in
the event torsades de pointes develops (Table 18).
In randomized studies of direct-current cardioversion, patients
pretreated with ibutilide were more often converted to sinus
rhythm than untreated controls and those in whom cardioversion
initially failed could more often be converted when the proce-
dure was repeated after treatment with ibutilide (280,281).
d. Prevention of Thromboembolism in Patients With Atrial
Fibrillation Undergoing Conversion
Randomized studies of antithrombotic therapy are lacking for
patients undergoing cardioversion of AF or atrial flutter, but in
case-control series the risk of thromboembolism was between
1% and 5% (265,282). The risk was near the low end of this
spectrum when anticoagulation (INR 2.0 to 3.0) was given for 3
to 4 wk before and after conversion (62,269). It is common
practice to administer anticoagulant drugs when preparing pa-
tients with AF of more than 2-d duration for cardioversion.
Manning et al (283) suggested that TEE might be used to
identify patients without LAA thrombus who do not require
anticoagulation, but a subsequent investigation (284) and meta-
analysis found this approach unreliable (285).
If most AF-associated strokes result from embolism of
stasis-induced thrombus from the LAA, then restoration and
maintenance of atrial contraction should logically reduce
thromboembolic risk. There is no evidence, however, that
cardioversion followed by prolonged maintenance of sinus
rhythm effectively reduces thromboembolism in AF patients.
Conversion of AF to sinus rhythm results in transient me-
chanical dysfunction of the LA and LAA (286) (“stunning”),
which can occur after spontaneous, pharmacological
(287,288), or electrical (288 –290) conversion of AF or after
radiofrequency catheter ablation of atrial flutter (91). Recov-
ery of mechanical function may be delayed, depending in part on
the duration of AF before conversion (291–293). This could
explain why some patients without demonstrable LA thrombus
on TEE before cardioversion subsequently experience thrombo-
embolic events (284). Presumably, thrombus forms during the
period of stunning and is expelled after the return of mechanical
function, explaining the clustering of thromboembolic events
during the first 10 d after cardioversion (84).
Patients with AF or atrial flutter in whom LAA thrombus
is identified by TEE are at high risk of thromboembolism and
should be anticoagulated for at least 3 wk prior to and 4 wk
after pharmacological or direct-current cardioversion. In a
multicenter study, 1222 patients with either AF persisting
longer than 2 d or atrial flutter and previous AF (294) were
randomized to a TEE-guided or conventional strategy. In the
group undergoing TEE, cardioversion was postponed when
thrombus was identified, and warfarin was administered for 3
wk before TEE was repeated to confirm resolution of throm-
bus. Anticoagulation with heparin was used briefly before
cardioversion and with warfarin for 4 wk after cardioversion.
The other group received anticoagulation for 3 wk before and
4 wk after cardioversion without intercurrent TEE. Both
approaches were associated with comparably low risks of
stroke (0.81% with the TEE approach and 0.50% with the
conventional approach) after 8 wk, there were no differences
in the proportion of patients achieving successful cardiover-
sion, and the risk of major bleeding did not differ signifi-
cantly. The clinical benefit of the TEE-guided approach was
limited to saving time before cardioversion.
Anticoagulation is recommended for 3 wk prior to and 4
wk after cardioversion for patients with AF of unknown
duration or with AF for longer than 48 h. Although LA
thrombus and systemic embolism have been documented in
patients with AF of shorter duration, the need for anticoagu-
lation is less clear. When acute AF produces hemodynamic
instability in the form of angina pectoris, MI, shock, or
pulmonary edema, immediate cardioversion should not be
delayed to deliver therapeutic anticoagulation, but intrave-
nous unfractionated heparin or subcutaneous injection of a
low-molecular-weight heparin should be initiated before car-
dioversion by direct-current countershock or intravenous
antiarrhythmic medication.
Protection against late embolism may require continuation
of anticoagulation for a more extended period after the
procedure, and the duration of anticoagulation after cardio-
version depends both on the likelihood that AF will recur in
an individual patient with or without symptoms and on the
intrinsic risk of thromboembolism. Late events are probably
due to both the development of thrombus as a consequence of
atrial stunning and the delayed recovery of atrial contraction
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after cardioversion. Stroke or systemic embolism has been
reported in patients with atrial flutter undergoing cardiover-
sion (295–297), and anticoagulation should be considered
with either the conventional or TEE-guided strategy. TEE-
guided cardioversion of atrial flutter has been performed with
a low rate of systemic embolism, particularly when patients
are stratified for other risk factors on the basis of clinical
and/or TEE features.
6. Maintenance of Sinus Rhythm
a. Pharmacological Therapy
Whether paroxysmal or persistent, AF is a chronic disorder,
and recurrence at some point is likely in most patients
(299 –301). Many patients eventually need prophylactic anti-
arrhythmic drug therapy to maintain sinus rhythm, suppress
symptoms, improve exercise capacity and hemodynamic
function, and prevent tachycardia-induced cardiomyopathy
due to AF. Because factors that predispose to recurrent AF
(advanced age, HF, hypertension, LA enlargement, and LV
dysfunction) are risk factors for thromboembolism, the risk of
stroke may not be reduced by correction of the rhythm
disturbance. Trials in which rate versus rhythm control
strategies were compared in patients with persistent and
paroxysmal AF (124,126,127,130,132) found no reduction in
death, disabling stroke, hospitalizations, new arrhythmias, or
thromboembolic complications in the rhythm control group.
b. Predictors of Recurrent Atrial Fibrillation
Most patients with AF, except those with postoperative or
self-limited AF secondary to transient or acute illness, even-
tually experience recurrence. Risk factors for frequent recur-
rence of paroxysmal AF (more than 1 episode per month)
include female gender and underlying heart disease (302). In
1 study of patients with persistent AF, the 4-y arrhythmia-free
survival rate was less than 10% after single-shock direct-
current cardioversion without prophylactic drug therapy
(300). Predictors of recurrences within that interval included
hypertension, age over 55 y, and AF duration of longer than
3 mo. Serial cardioversions and prophylactic drug therapy
resulted in freedom from recurrent AF in approximately 30%
of patients (300), and with this approach predictors of
recurrence included age over 70 y, AF duration beyond 3 mo,
and HF (300). Other risk factors for recurrent AF include LA
enlargement and rheumatic heart disease.
Various benign arrhythmias, especially ventricular and
supraventricular premature beats, bradycardia, and short pe-
riods of sinus arrest, may arise after cardioversion and
commonly subside spontaneously (266). More dangerous
arrhythmias, such as ventricular tachycardia and fibrillation,
may arise in the face of hypokalemia, digitalis intoxication, or
improper synchronization (267,268). Serum potassium levels
should be in the normal range for safe, effective cardiover-
sion. Cardioversion is contraindicated in cases of digitalis
toxicity because resulting ventricular tachyarrhythmia may be
difficult to terminate.
In patients with long-standing AF, cardioversion com-
monly unmasks underlying sinus node dysfunction. A slow
ventricular response to AF in the absence of drugs that slow
conduction across the AV node may indicate an intrinsic
conduction defect. The patient should be evaluated before
cardioversion with this in mind so a transvenous or transcu-
taneous pacemaker can be used prophylactically (269).
c. General Approach to Antiarrhythmic Drug Therapy
Before administering any antiarrhythmic agent, reversible
precipitants of AF should be identified and corrected. Most
are related to coronary or valvular heart disease, hyperten-
sion, or HF. Patients who develop AF in association with
alcohol intake should abstain from alcohol consumption.
Indefinite antiarrhythmic treatment is seldom prescribed after
a first episode, although a period of several weeks may help
stabilize sinus rhythm after cardioversion. Similarly, patients
experiencing breakthrough arrhythmias may not require a
change in antiarrhythmic drug therapy when recurrences are
infrequent and mild. Beta-adrenergic antagonist medication
may be effective in patients who develop AF only during
exercise, but a single, specific inciting cause rarely accounts
for all episodes of AF, and the majority of patients do not
sustain sinus rhythm without antiarrhythmic therapy. Selec-
tion of an appropriate agent is based first on safety, tailored to
whatever underlying heart disease may be present, consider-
ing the number and pattern of prior episodes of AF (303).
In patients with lone AF, a beta blocker may be tried first,
but flecainide, propafenone, and sotalol are particularly ef-
fective. Amiodarone and dofetilide are recommended as
alternative therapies. Quinidine, procainamide, and disopyr-
amide are not favored unless amiodarone fails or is contra-
indicated. For patients with vagally induced AF, however, the
anticholinergic activity of long-acting disopyramide makes it
a relatively attractive theoretical choice. In that situation,
flecainide and amiodarone represent secondary and tertiary
treatment options, respectively, whereas propafenone is not
recommended because its (weak) intrinsic beta-blocking ac-
tivity may aggravate vagally mediated paroxysmal AF. In
patients with adrenergically mediated AF, beta blockers
represent first-line treatment, followed by sotalol and amiod-
arone. In patients with adrenergically mediated lone AF,
amiodarone represents a less appealing selection. Vagally
induced AF can occur by itself, but more typically it is part of
the overall patient profile. In patients with nocturnal AF, the
possibility of sleep apnea should be considered.
When treatment with a single antiarrhythmic drug fails,
combinations may be tried. Useful combinations include a
beta blocker, sotalol, or amiodarone with a class IC agent.
The combination of a calcium channel blocker, such as
diltiazem, with a class IC agent, such as flecainide or
propafenone, is advantageous in some patients. A drug that is
initially safe may become proarrhythmic if coronary disease
or HF develops or if the patient begins other medication that
exerts a proarrhythmic interaction. Thus, the patient should
be alerted to the potential significance of such symptoms as
syncope, angina, or dyspnea and warned about the use of
noncardiac drugs that might prolong the QT interval.
The optimum method for monitoring antiarrhythmic drug
treatment varies with the agent involved as well as with
patient factors. Prospectively acquired data on upper limits of
drug-induced prolongation of QRS duration or QT interval
are not available. With class IC drugs, prolongation of the
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QRS interval should not exceed 50%. Exercise testing may
help detect QRS widening that occurs only at rapid heart rates
(use-dependent conduction slowing). For class IA or class III
drugs, with the possible exception of amiodarone, the cor-
rected QT interval in sinus rhythm should be kept below 520
ms. During follow-up, plasma potassium and magnesium
levels and renal function should be checked periodically
because renal insufficiency leads to drug accumulation and
predisposes to proarrhythmia. In individual patients, serial
noninvasive assessment of LV function is indicated, espe-
cially when clinical HF develops during treatment of AF.
d. Selection of Antiarrhythmic Agents in Patients With
Cardiac Diseases
Pharmacological management algorithms to maintain sinus
rhythm in patients with AF (see Figs. 7, 8, 9, and 10) and
applications in specific cardiac disease states are based on
available evidence and extrapolated from experience with
these agents in other situations.
Heart failure.
Patients with HF are particularly prone to the ventricular
proarrhythmic effects of antiarrhythmic drugs because of
myocardial vulnerability and electrolyte imbalance. Random-
ized trials have demonstrated the safety of amiodarone and
dofetilide (given separately) in patients with HF (200,304),
and these are the recommended drugs for maintenance of
sinus rhythm in patients with AF in the presence of HF (Fig.
9). Patients with LV dysfunction and persistent AF should be
treated with beta blockers and ACE inhibitors and/or angio-
tensin II receptor antagonists, because these agents help
control the heart rate, improve ventricular function, and
prolong survival (305–308).
Coronary artery disease.
In stable patients with CAD, beta blockers may be considered
first, although their use is supported by only 2 studies (309,310)
and data on efficacy for maintenance of sinus rhythm in patients
with persistent AF after cardioversion are not convincing (310).
Sotalol has substantial beta-blocking activity and may be the
preferred initial antiarrhythmic agent in patients with AF who
have ischemic heart disease because it is associated with less
long-term toxicity than amiodarone. Amiodarone increases the
risk of bradyarrhythmia requiring permanent pacemaker implan-
tation in elderly patients with AF who have previously sustained
MI (311) but may be preferred over sotalol in patients with HF
(312,313). Neither flecainide nor propafenone is recommended
in these situations, but quinidine, procainamide, and disopyr-
amide may be considered as third-line choices in patients with
coronary disease. The DIAMOND-MI (Danish Investigations of
Arrhythmias and Mortality on Dofetilide in Myocardial Infarc-
tion) trial (314) involved selected post-MI patients in whom the
antiarrhythmic benefit of dofetilide balanced the risk of proar-
rhythmic toxicity, making this a second-line antiarrhythmic
agent. In patients with coronary disease who have not developed
MI or HF, however, it is uncertain whether the benefit of
dofetilide outweighs risk, and more experience is needed before
this drug can be recommended for such patients (Fig. 9).
Hypertensive heart disease.
Hypertension is the most prevalent and potentially modi-
fiable independent risk factor for the development of AF and
its complications, including thromboembolism (315,316).
Blood pressure control may become an opportune strategy for
the prevention of AF. Patients with LVH may face an
increased risk of torsades de pointes related to early ventric-
ular afterdepolarizations (303,317). Thus, class IC agents and
amiodarone are preferred over type IA and type III antiar-
rhythmic agents as first-line therapy. In the absence of
ischemia or LVH, both propafenone and flecainide are
reasonable choices. Proarrhythmia with 1 agent does not
predict this response to another, and patients with LVH who
develop torsades de pointes during treatment with a class III
agent may tolerate a class IC agent. Amiodarone prolongs the
QT interval but carries a very low risk of ventricular
proarrhythmia. Its extracardiac toxicity relegates it to second-
line therapy in these individuals, but it becomes a first-line
agent in the face of substantial LVH. When amiodarone and
sotalol either fail or are inappropriate, disopyramide, quini-
dine, or procainamide represents a reasonable alternative.
Beta blockers may be the first line of treatment to maintain
sinus rhythm in patients with MI, HF, and hypertension.
Compared to patients with lone AF, those with hypertension
are more likely to maintain sinus rhythm after cardioversion
of persistent AF when treated with a beta blocker (318).
Drugs modulating the RAAS reduce structural cardiac
changes (319), and ACE inhibition was associated with a
lower incidence of AF compared with calcium channel
blockade in patients with hypertension during 4.5 y of
follow-up in a retrospective, longitudinal cohort study from a
database of 8 million patients in a managed care setting (320).
In patients at increased risk of cardiovascular events, therapy
with either the ACE inhibitor ramipril (321–323) or angio-
tensin receptor antagonist, losartan (324,325) lowered the risk
of stroke. A similar benefit has been reported with perindopril
in a subset of patients with AF treated for prevention of
recurrent stroke (326). New-onset AF and stroke were sig-
nificantly reduced by losartan as compared to atenolol in
hypertensive patients with ECG-documented LVH, despite a
similar reduction of blood pressure (16). The benefit of
losartan was greater in patients with AF than in those with
sinus rhythm for the primary composite endpoint (cardiovas-
cular mortality, stroke, and MI) and for cardiovascular
mortality alone (327). Presumably, the beneficial effects of
beta blockers and drugs modulating the RAAS are at least
partly related to lower blood pressure.
7. Nonpharmacological Therapy for Atrial Fibrillation
The inconsistent efficacy and potential toxicity of antiar-
rhythmic drug therapies have stimulated exploration of a
wide spectrum of alternative nonpharmacological therapies
for the prevention and control of AF.
a. Surgical Ablation
A decade of research in the 1980s demonstrated the critical
elements necessary to cure AF surgically, including tech-
niques that entirely eliminate macroreentrant circuits in the
atria while preserving sinus node and atrial transport func-
tions. The surgical approach was based on the hypothesis that
reentry is the predominant mechanism responsible for the
development and maintenance of AF (328), leading to the
concept that atrial incisions at critical locations would create
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barriers to conduction and prevent sustained AF. The proce-
dure developed to accomplish these goals was based on the
concept of a geographical maze, accounting for the term “maze”
procedure used to describe this type of cardiac operation (329).
Since its introduction, the procedure has gone through 3
iterations (maze I, II, and III) using cut-and-sew techniques
that ensure transmural lesions to isolate the PV, connect these
dividing lines to the mitral valve annulus, and create electrical
barriers in the RA that prevent macroentrant rhythms—atrial
flutter or AF—from becoming sustained (330). Success rates
of around 95% over 15 y of follow-up have been reported in
patients undergoing mitral valve surgery (331). Other studies
suggest success rates around 70% (332). Atrial transport
function is maintained and, when combined with amputation
or obliteration of the LAA, postoperative thromboembolic
events are substantially reduced. Risks include death (less
than 1% when performed as an isolated procedure), the need
for permanent pacing (with right-sided lesions), recurrent
bleeding requiring re-operation, impaired atrial transport
function, delayed atrial arrhythmias (especially atrial flutter),
and atrioesophageal fistula.
Despite its high success rate, the maze operation has not been
widely adopted other than for patients undergoing cardiac
surgery because of the need for cardiopulmonary bypass. A wide
variety of less invasive modifications are under investigation,
including thoracoscopic and catheter-based epicardial tech-
niques (332). If the efficacy of these adaptations approaches that
of the endocardial maze procedure and they can be performed
safely, they may become acceptable alternatives for a larger
proportion of patients with AF.
b. Catheter Ablation
Early radiofrequency catheter ablation techniques emulated
the surgical maze procedure by introducing linear scars in the
atrial endocardium (333). While the success rate was approx-
imately 40% to 50%, a relatively high complication rate
diminished enthusiasm for this approach (38). The observa-
tion that potentials arising in or near the ostia of the PV often
provoked AF and demonstration that elimination of these foci
abolished AF escalated enthusiasm for catheter-based abla-
tion (38). Initially, areas of automaticity within the PV were
targeted, and in a series of 45 patients with paroxysmal AF,
62% became free of symptomatic AF over a mean follow-up
of 8 mo, but 70% required multiple procedures (38). In
another study, the success rate was 86% over a 6-mo
follow-up (334). Subsequent research has demonstrated that
potentials may arise in multiple regions of the RA and LA,
including the LA posterior wall, superior vena cava, vein of
Marshall, crista terminalis, interatrial septum, and coronary sinus
(335), and modification of the procedures has incorporated linear
LA ablation, mitral isthmus ablation, or both for selected patients
(336).
The technique of ablation has continued to evolve from
early attempts to target individual ectopic foci within the PV
to circumferential electrical isolation of the entire PV mus-
culature. In a series of 70 patients, 73% were free from AF
following PV isolation without antiarrhythmic medications
during a mean follow-up of 4 mo, but 29 patients required a
second procedure to reach this goal. However, postablation
AF may occur transiently in the first 2 mo (337). Advances
involving isolation of the PV at the antrum using a circular
mapping catheter, guided by intracardiac echocardiography,
have reportedly yielded approximately 80% freedom of
recurrent AF or atrial flutter after the first 2 mo in patients
with paroxysmal AF (338), but success rates were lower in
patients with cardiac dysfunction (339). Still another ap-
proach (340,341) uses a nonfluoroscopic guidance system
and radiofrequency energy delivered circumferentially out-
side the ostia of the PV. In a series of 26 patients, 85% were
free of recurrent AF during a mean follow-up of 9 mo,
including 62% taking no antiarrhythmic medications. The
accumulated experience involves nearly 4000 patients (341),
with approximately 90% success in cases of paroxysmal AF
and 80% in cases of persistent AF (339,342,343).
Another anatomic approach to radiofrequency catheter
ablation targets complex fractionated electrograms (344) with
91% efficacy reported at 1 y. Restoration of sinus rhythm
after catheter ablation for AF significantly improved LV
function, exercise capacity, symptoms, and quality of life
(usually within the first 3 to 6 mo), even in the presence of
concurrent heart disease and when ventricular rate control
was adequate before ablation (345). While that study lacked
a control group of patients with HF, in another study catheter
ablation of AF was associated with reduced mortality and
morbidity due to HF and thromboembolism (346).
In selected patients, radiofrequency catheter ablation of the
AV node and pacemaker insertion decreased symptoms of AF
and improved quality-of-life scores compared with medica-
tion therapy (140 –142,347–349). A meta-analysis of 10
studies of patients with AF (143) found improvement in both
symptoms and quality-of-life scores after ablation and pacing.
Although these studies involved selected patients who re-
mained in AF, the consistent improvement suggests that
quality of life was impaired before intervention.
Despite these advances, the long-term efficacy of catheter
ablation to prevent recurrent AF requires further study.
Available data demonstrate 1 or more y free from recurrent
AF in most (albeit carefully selected) patients (350 –352). It is
important to bear in mind, however, that AF can recur
without symptoms and be unrecognized by the patient or the
physician. Therefore, it remains uncertain whether apparent
cures represent elimination of AF or transformation into an
asymptomatic form of paroxysmal AF. The distinction has
important implications for the duration of anticoagulation
therapy in patients with risk factors for stroke associated with
AF. In addition, little information is available about the late
success of ablation in patients with HF and other advanced
structural heart disease, who may be less likely to enjoy
freedom from AF recurrence.
Complications of catheter ablation include the adverse
events associated with any cardiac catheterization procedure
in addition to those specific to ablation of AF. Major
complications have been reported in about 6% of procedures
and include PV stenosis, thromboembolism, atrioesophageal
fistula, and LA flutter (343). The initial ablation approach
targeting PV ectopy was associated with an unacceptably
high rate of PV stenosis (334,353), but the incidence has
dramatically decreased as a result of changes in technique.
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Current approaches avoid delivering radiofrequency energy
within the PV and instead target areas outside the veins to isolate
the ostia from the remainder of the LA conducting tissue. Use of
intracardiac echocardiographically detected microbubble forma-
tion to titrate radiofrequency energy has also been reported to
reduce the incidence of PV stenosis (338).
Embolic stroke is among the most serious complications of
catheter-based ablation procedures in patients with AF. The
incidence varies from 0% to 5%. A higher intensity of
anticoagulation reduces the risk of thrombus formation dur-
ing ablation (354). Based on limited data from dose-
comparison studies, it seems likely that more aggressive
anticoagulation may reduce the incidence of thromboembo-
lism associated with catheter-based ablation of AF.
Atrioesophageal fistula has been reported with both the
circumferential Pappone approach (355,356) and the Hais-
saguerre PV ablation techniques (356) but is relatively rare. This
complication may be more likely to occur when extensive
ablative lesions are applied to the posterior LA wall, increasing
the risk of atrial perforation. The typical manifestations include
sudden neurological symptoms or endocarditis, and the outcome
in most cases is, unfortunately, fatal. Depending on the ablation
approach, LA flutter may develop during treatment of AF (357),
and this is amenable to further ablation (358).
Future directions in catheter-based ablation therapy for
atrial fibrillation.
Catheter-directed ablation of AF represents a substantial
achievement that promises better therapy for a large number
of patients presently resistant to pharmacological or electrical
conversion to sinus rhythm. The limited available studies
suggest that catheter-based ablation offers benefit to selected
patients with AF, but these studies do not provide convincing
evidence of optimum catheter positioning or absolute rates of
treatment success. Identification of patients who might ben-
efit from ablation must take into account both potential
benefits and short- and long-term risks. Rates of success and
complications vary, sometimes considerably, from one study
to another because of patient factors, patterns of AF, criteria
for definition of success, duration of follow-up, and technical
aspects. Registries of consecutive case series should incorpo-
rate clear and prospectively defined outcome variables.
Double-blind studies are almost impossible to perform, yet
there is a need for randomized trials in which evaluation of
outcomes is blinded as to treatment modality. A comprehen-
sive evaluation of the favorable and adverse effects of various
ablation techniques should include measures of quality of life
and recurrence rates compared with pharmacological strate-
gies for rhythm control and, when this is not successful, with
such techniques of rate control as AV node ablation and
pacing. Generation of these comparative data over relatively
long periods of observation would address the array of
invasive and conservative management approaches available
for management of patients with AF and provide a valuable
foundation for future practice guidelines.
c. Suppression of Atrial Fibrillation Through Pacing
Several studies have examined the role of atrial pacing, either
in the RA alone or in more than 1 atrial location, to prevent
recurrent paroxysmal AF. In patients with symptomatic
bradycardia, the risk of AF is lower with atrial than with
ventricular pacing (359). In patients with sinus node dysfunc-
tion and normal AV conduction, data from several random-
ized trials support atrial or dual-chamber rather than ventric-
ular pacing for prevention of AF (360 –363). The mechanisms
by which atrial pacing prevents AF in patients with sinus
node dysfunction include prevention of bradycardia-induced
dispersion of repolarization and suppression of atrial prema-
ture beats. Atrial or dual-chamber pacing also maintains AV
synchrony, preventing retrograde ventriculoatrial conduction,
which can cause valvular regurgitation and stretch-induced
changes in atrial electrophysiology. When ventricular pacing
with dual-chamber devices is unavoidable because of con-
comitant disease of the AV conduction system, the evidence
is less clear that atrial-based pacing is superior. Although
atrial-based pacing is associated with a lower risk of AF and
stroke than ventricular-based pacing in patients requiring
pacemakers for bradyarrhythmias, the value of pacing as a
primary therapy for prevention of recurrent AF has not been
proven.
d. Internal Atrial Defibrillators
There has been an interest in internal cardioversion of AF for
the past 10 y (135). Intense basic and clinical research to find
tolerable shock waveforms led to evaluation of an implant-
able device capable of both atrial sensing and cardioversion
and ventricular sensing and pacing in 290 patients with mean
LV ejection fraction greater than 50% who had not responded
satisfactorily to therapy with 4 antiarrhythmic drugs (135).
The rate of conversion to sinus rhythm was 93%. As
spontaneous episodes were treated quickly, the interval be-
tween episodes of AF lengthened. Several available devices
combining both atrial cardioversion and ventricular defibril-
lation capabilities with dual-chamber sensing and pacing
have been designed to treat both atrial and ventricular
arrhythmias by pacing before delivering low- or high-energy
shocks.
An important limitation of atrial defibrillators, unrelated to
efficacy, is that most patients find discharge energies over
1 J uncomfortable. Candidates for atrial cardioverters with
infrequent episodes of poorly tolerated AF are typically also
candidates for catheter ablation. As a result, implanted
devices have limited utility, except for patients with LV
dysfunction who are candidates for implantable ventricular
defibrillators.
C. Primary Prevention
Although measures aimed at the primary prevention of AF
have not been widely investigated, it has been suggested that
atrial or AV synchronous pacing may reduce the incidence of
subsequent AF in patients with bradycardia compared with
ventricular pacing (359,360). On the other hand, studies in
patients with intermittent atrial tachyarrhythmias failed to
illustrate a general benefit of atrial pacing (360,365,366).
Another potential avenue for primary prevention has been
suggested following secondary analysis of placebo-controlled
trials of treatment with ACE inhibitors (56,367). In the LIFE
(Losartan Intervention For End Point Reduction in Hyperten-
sion) (16) and CHARM (Candesartan in Heart Failure As-
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sessment of Reduction in Mortality and Morbidity) (368)
trials, the angiotensin receptor antagonists losartan and can-
desartan reduced the incidence of AF in hypertensive patients
with LVH (16) and symptomatic HF (21,368), respectively.
These results, together with their favorable safety profile
compared with antiarrhythmic agents, suggest a role for ACE
inhibitor or angiotensin receptor antagonists for primary
prevention of initial or recurrent episodes of AF associated
with hypertension, MI, HF, or diabetes mellitus. An overview
of 11 clinical trials involving more than 56 000 patients with
different underlying cardiovascular diseases suggests that
ACE inhibitors or angiotensin receptor blockers may reduce
the occurrence and recurrence of AF (55).
Yet inadequately explored, the use of statins has also been
suggested to protect against AF (369,370), and dietary lipid
components may influence the propensity of patients to develop
AF (371). In 449 patients with CAD followed for 5 y, statin
therapy reduced the incidence of AF—an effect not observed
with other lipid-lowering drugs (369). Insufficient data are
available at this time to permit recommendations for primary
prevention of AF in populations at risk using dietary interven-
tions, pharmacological interventions, or pacing or other devices.
IX. Proposed Management Strategies
A. Overview of Algorithms for Management of
Patients With Atrial Fibrillation
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or perma-
nent), underlying conditions, and decisions about restoration
and maintenance of sinus rhythm, control of the ventricular
rate, and antithrombotic therapy. These issues are addressed
in the various management algorithms for each presentation
of AF (see Figs. 7, 8, 9, and 10).
1. Newly Discovered Atrial Fibrillation
It is not always clear whether the initial presentation of AF is
actually the first episode, particularly in patients with mini-
mal or no symptoms related to the arrhythmia. In patients
who have self-limited episodes of AF, antiarrhythmic drugs
are usually unnecessary to prevent recurrence unless AF is
associated with severe symptoms related to hypotension,
myocardial ischemia, or HF. Regarding anticoagulation, the
results of the AFFIRM study (132) indicate that patients with
AF who are at high risk for stroke on the basis of identified
risk factors generally benefit from anticoagulation even after
sinus rhythm has been restored. Therefore, unless there is a
clear reversible precipitating factor for AF, such as hyperthy-
roidism that has been corrected, the diagnosis of AF in a
patient with risk factors for thromboembolism should prompt
long-term anticoagulation.
When AF persists, one option is to accept progression to
permanent AF, with attention to antithrombotic therapy and
control of the ventricular rate. Although it may seem reason-
able to make at least one attempt to restore sinus rhythm, the
AFFIRM study showed no difference in survival or quality of
life with rate control compared to a rhythm control strategies
(132). Other trials that addressed this issue reached similar
conclusions (124,126,127,130). Hence, the decision to at-
tempt restoration of sinus rhythm should be based on the
severity of arrhythmia-related symptoms and the potential
risk of antiarrhythmic drugs. If the decision is made to
attempt to restore and maintain sinus rhythm, then anticoag-
ulation and rate control are important before cardioversion.
Although long-term antiarrhythmic therapy may not be
needed to prevent recurrent AF after cardioversion, short-
term therapy may be beneficial. In patients with AF that has
been present for longer than 3 mo, early recurrence is
common after cardioversion. In such cases, antiarrhythmic
medication may be initiated before cardioversion (after ade-
quate anticoagulation) to reduce the likelihood of recurrence,
and the duration of drug therapy would be brief (e.g., 1 mo).
2. Recurrent Paroxysmal Atrial Fibrillation
In patients who experience brief or minimally symptomatic
recurrences of paroxysmal AF, it is reasonable to avoid
antiarrhythmic drugs, but troublesome symptoms generally
call for suppressive antiarrhythmic therapy. Rate control and
prevention of thromboembolism are appropriate in both
situations. In a given patient, several antiarrhythmic drugs
may be effective and the initial selection is based mainly on
safety and tolerability (Fig. 9). For individuals with no or
minimal heart disease, flecainide, propafenone, or sotalol is
recommended as initial antiarrhythmic therapy because they
are generally well tolerated and carry relatively little risk of
toxicity. For patients with recurrent episodes of symptomatic
AF who tolerate these agents, an as-needed, pill-in-the-pocket
approach may reduce the risk of toxicity compared with
sustained therapy. When these drugs prove ineffective or are
associated with side effects, the second- or third-line choices
include amiodarone, dofetilide, disopyramide, procainamide,
or quinidine, all of which carry greater potential for adverse
reactions. As an alternative to treatment with amiodarone or
dofetilide when first-line antiarrhythmic drugs fail or are not
tolerated, PV isolation or LA substrate modification may be
considered. When a consistent initiating scenario suggests
vagally mediated AF, drugs such as disopyramide or flecain-
ide are appropriate initial agents, and a beta blocker or sotalol
is suggested for patients with adrenergically induced AF. In
particularly symptomatic patients, nonpharmacological op-
tions such as LA ablation may be considered when antiar-
rhythmic drug treatment alone fails to control the arrhythmia.
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension. Other
types of heart disease can be associated with AF, and the
clinician must determine which category best describes the
individual patient. For patients with HF, safety data support the
selection of amiodarone or dofetilide to maintain sinus rhythm.
Patients with CAD often require beta-blocker medication, and
sotalol, a drug with both beta-blocking activity and primary
antiarrhythmic efficacy, is considered first, unless the patient has
HF. Amiodarone and dofetilide are considered secondary agents,
and the clinician should consider disopyramide, procainamide,
or quinidine on an individual basis.
The selection of antiarrhythmic drugs for patients with a
history of hypertension is confounded by the dearth of
prospective, controlled trials comparing the safety and effi-
cacy of drug therapy for AF. In patients with hypertension
without LVH, drugs such as flecainide and propafenone,
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which do not prolong repolarization or the QT interval, may
offer a safety advantage and are recommended first. If these
agents either prove ineffective or produce side effects, then
amiodarone, dofetilide, or sotalol represents an appropriate
secondary choice. Disopyramide, procainamide, and quini-
dine are considered third-line agents in this situation. Hyper-
trophied myocardium may be prone to proarrhythmic toxicity
and torsades de pointes ventricular tachycardia. Amiodarone
is suggested as first-line therapy in patients with LVH
because of its relative safety compared with several other
agents. Because neither ECG nor echocardiography reliably
detects LVH as defined by measurement of myocardial mass,
clinicians may face a conundrum.
The scarcity of data from randomized trials of antiarrhyth-
mic medications for treatment of patients with AF applies
generally to all patient groups. Accordingly, the drug-
selection algorithms presented here have been developed by
consensus and are subject to revision as additional evidence
emerges.
3. Recurrent Persistent Atrial Fibrillation
Patients with minimal or no symptoms referable to AF who
have undergone at least one attempt to restore sinus rhythm
may remain in AF after recurrence, with therapy for rate
control and prevention of thromboembolism as needed. Al-
ternatively, those with symptoms favoring sinus rhythm
should be treated with an antiarrhythmic agent (in addition to
medications for rate control and anticoagulation) before
cardioversion. The selection of an antiarrhythmic drug should
be based on the same algorithm used for patients with
recurrent paroxysmal AF. If patients remain symptomatic
with heart rate control and antiarrhythmic medication is either
not tolerated or ineffective, then nonpharmacological thera-
pies may be considered. These include LA ablation, the maze
operation, or AV nodal ablation and pacing.
4. Permanent Atrial Fibrillation
Permanent AF is the designation given to cases in which
sinus rhythm cannot be sustained after cardioversion of AF or
when the patient and physician have decided to allow AF to
continue without further efforts to restore sinus rhythm. It is
important to maintain control of the ventricular rate and to
use antithrombotic therapy, as outlined elsewhere in this
document, for all patients in this category.
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APPENDIX III: Abbreviations
ACE angiotensin-converting enzyme
ACT activated clotting time
ACTIVE-W Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events
ADONIS American-Australian Trial with Dronedarone in Atrial Fibrillation or Flutter Patients for Maintenance of Sinus Rhythm
AF atrial fibrillation
AFASAK Copenhagen Atrial Fibrillation, Aspirin, Anticoagulation
AF-CHF Atrial Fibrillation and Congestive Heart Failure
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
AFI Atrial Fibrillation Investigators
ALFA Etude en Activité Libérale sur la Fibrillation Auriculaire
ANP atrial naturetic peptide
APT Ablate and Pace Trial
ARCH Amiodarone Reduction in Coronary Heart
ATRIA Anticoagulation and Risk Factors in Atrial Fibrillation
AV atrioventricular
BAATAF Boston Area Anticoagulation Trial for Atrial Fibrillation
BNP B-type natriuretic peptide
CABG coronary artery bypass
CAD coronary artery disease
CAFA Canadian Atrial Fibrillation Anticoagulation
CAPRICORN Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction trial
CHADS2 Cardiac Failure, Hypertension, Age, Diabetes, Stroke Doubled
CHAMP Combined Hemotherapy and Mortality Prevention Study
CHARM Candesartan in Heart failure, Assessment of Reduction in Mortality and morbidity
CHF-STAT Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure
CI confidence interval
CIBIS Cardiac Insufficiency Bisoprolol Study
COMET Carvedilol Or Metoprolol European Trial
CONSENSUS Co-operative North Scandinavian Enalapril Survival Study
COPERNICUS Carvedilol Prospective Randomized Cumulative Survival
COPD Chronic obstructive pulmonary disorder
CRP C-reactive protein
CTGF connective tissue growth factor
CVF-1 type 1 collagen volume fraction
DIAMOND Danish Investigations of Arrhythmias and Mortality on Dofetilide
DIAMOND-MI Danish Investigations of Arrhythmia and Mortality on Dofetilide–Myocardial Infarction
EAFT European Atrial Fibrillation Trial
ECG electrocardiogram
ELAT Embolism in the Left Atrial Thrombi
EMERALD European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide study
EP electrophysiological
ERK-2-mRNA extracellular signal-regulated kinase messenger-RNA
ERP effective refractory period
ESPS II European Stroke Prevention Study II
EURIDIS European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for Maintenance of Sinus Rhythm
FFAACS The French Fluindione-Aspirin Combination in High Risk Patients With AF
GESICA Grupo Estudio de la Sobrevida en la Insufficienca Cardiaca en Argentina (V)
GUSTO-1 Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries
HCM hypertrophic cardiomyopathy
HF heart failure
HOT CAFÉ How to Treat Chronic Atrial Fibrillation
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HOT CAFÉ How to Treat Chronic Atrial Fibrillation
HRV heart rate variability
IMP-2 atrial insulin-like growth factor-II mRNA-binding protein 2
INR international normalized ratio
IRAF immediate recurrence of atrial fibrillation
IVC inferior vena cava
LA left atrium
LAA LA appendage
LASAF Low-dose Aspirin, Stroke, Atrial Fibrillation
LIFE Losartan Intervention For End Point Reduction in Hypertension study
LMWH low-molecular-weight heparin
LV left ventricle
MERIT-HF Metropolol CR/XL Randomized Intervention Trial in Congestive Heart Failure
MI myocardial infarction
MMP-2 matrix metalloproteinase 2
NASPEAF National Study for Prevention of Embolism in Atrial Fibrillation
PAFAC Prevention of atrial fibrillation after cardioversion
PAPABEAR Prevention of Arrhythmias that Begin Early after Revascularization, Valve Replacement, or Repair
PATAF Prevention of Arterial Thromboembolism in Atrial Fibrillation
PAVE Post AV Node Ablation Evaluation
PIAF Pharmacological Intervention in Atrial Fibrillation
PV pulmonary veins
RA right atrium
RAAS renin-angiotensin-aldosterone system
RACE Rate Control vs. Electrical cardioversion for persistent atrial fibrillation
RV right ventricular
SAFE-T Sotalol Amiodarone Atrial Fibrillation Efficacy Trial
SAFIRE-D Symptomatic Atrial Fibrillation Investigative Research on Dofetilide
SEC spontaneous echo contrast
SIFA Studio Italiano Fibrillazione Atriale
SOLVD Studies of Left Ventricular Dysfunction
SOPAT Suppression of paroxysmal atrial tachyarrhythmias
SPAF Stroke Prevention in Atrial Fibrillation
SPINAF Stroke Prevention in Nonrheumatic Atrial Fibrillation
SPORTIF Stroke Prevention using an Oral Direct Thrombin Inhibitor In Patients with Atrial Fibrillation
SRAF subacute recurrence of atrial fibrillation
STAF Strategies of Treatment of Atrial Fibrillation
SVC superior vena cava
TEE transesophageal echocardiography
TGF-beta1 transforming growth factor-beta1
TIA transient ischemic attack
TRACE Trandolapril Cardiac Evaluation
UK-TIA The United Kingdom transient ischaemic attack aspirin trial
Val-HeFT Valsartan Heart Failure Trial
VF ventricular fibrillation
WPW Wolff-Parkinson-White
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